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Neurodegenerative disorders are a mayor health risk for the aging population of the world. The 
aggregation of tau constitutes a mayor hallmark of Alzheimer disease (AD) and other neurological 
diseases such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal 
dementias with parkinsonism liked to chromosome 17. Tau spreads in a prion like manner via the 
formation of disease specific fibrils. The cause of tau aggregation in neurodegenerative disorders 
has yet remained unclear. We were now able to show, that the archaic yeast prion domain Sup35NM 
is able to cross-species cross-seed human tau. In tau transgenic P301S mice this led to an 
accentuation of tau pathology in the hippocampus of Sup35NM inoculated mice. In vitro seeding of 
tau monomers with Sup35NM fibrils led to the accelerated formation of tau fibrils. These fibrils 
showed a characteristic corkscrew-like pattern. In AD, early tau aggregation occurs in the olfactory 
bulb. The nasal sensors are in close contact to exogenous agents and the microbiome present in 
the nasopharyngeal cavity, and they are anatomically connected to the limbic system, which is also 
affected early in AD. Together our results allow a novel perception of the prion world, in which archaic 
prions of the human microbiome are able to influence the aggregation of prion-like proteins like tau 
in neurodegenerative diseases. Understanding the initiation of prion formation in sporadic 
neurodegenerative disorders will be pivotal for the long-awaited generation of preventive or curative 
approaches for these devastating disorders.  
Another important aspect concerning the desired treatment of neurodegenerative diseases like 
tauopathies is the potential long term effect of neurotoxic stress caused by misfolded proteins like 
tau. We therefore investigated the long term effects of severe early neurotoxic tau stress in recovered 
transgenic P301SxTau62 mice. Counterintuitively, P301SxTAU62 tau mice which underwent 
transient severe paralysis in early life, and maintained their P301S tau expression, developed less 
tau pathology and even maintained a slightly better motor performance when aging, in comparison 
to their heterozygous P301S transgenic littermates, which were not exposed to early tau stress. In 
accordance with that, different from tau fibrils the tau oligomers detected in the brains of 
P301SxTAU62 tau mice were not able to cause tau fibrillization in human tau transgenic ALZ17 
mice. This is further evidence, that the structure of tau aggregates plays a crucial role when it comes 
to tau pathology spreading in the brain via prion-like template transmission. It also speaks for the 
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1.1.1 Alzheimer disease 
 
Alzheimer Disease (AD) is the most common form of senile dementia (Gupta et al., 2010) with age 
as the main risk factor. The incidence rate for AD increases from 0.08% per year in the age group of 
60-65 to 6.48% incidence rate per year in the age group of 85+ (Kawas et al., 2000). In 2013 in the 
US 84,767 deaths from AD were recorded, making it the sixth leading cause of death for the total 
population and the fifth leading cause of death for people older than 65 years (Gaugler et al., 2016). 
Between 2000 and 2013 deaths from AD increased by 71% and with an aging population this rate is 
predicted to rise even further (Gaugler et al., 2016). AD is characterized by two hallmark lesions: 
Extracellular plaques of amyloid-beta (Aβ) and the formation of neurofibrillary tangles (NFTs) and 
neuropil threads (NTs) by tau protein (Gaugler et al., 2016). The Aβ plaques are caused by an 
alteration of amyloid precursor protein (APP). Aβ builds deposits in the cortex, the limbic system and 
the walls of arteries and arterioles where they cause cerebral amyloid angiopathy (CAA). Structural 
alterations of the microtubule associated protein tau (MAPT) lead to a loss of function and 
fibrillization and cause a significant loss of synapses and neuronal loss. (López and DeKosky, 2008; 
Ellison et al., 2012). The clinical symptoms of AD start with deficits in recent memory and language 
difficulties, and will gradually progress to a global cognitive impairment.  During the early and middle 
phases of AD development, the alertness of patients is well preserved, and motoric and sensory 
functions are mainly intact. However, as subjects continue to worsen cognitively, a slowing of motor 
functions like gait and coordination can often lead to motoric limitations comparable to the ones 
observed in Parkinson patients (López and DeKosky, 2008; Gupta et al., 2010). Although over 90% 
of patients with AD appear to suffer from sporadic AD (SAD) (Chai, 2007) there are some genetic 
risk factors. Carriers of the apolipoprotein E, type 4 allele (APOE-ε4) have an increased risk to 
develop AD and a lower age of onset (Saunders et al., 1993). People with Down syndrome have a 
higher risk to develop AD early in life. This  abnormality has been correlated to the triplication and 




Autosomal dominant AD has a prevalence of less than 1% and is caused by mutations in APP, from 
which Aβ is cleaved, or by mutations in presenilin 1 (PS1) and presenilin 2 (PS2) which are part of 
the γ-secretase complex cleaving APP (Van Cauwenberghe, Van Broeckhoven and Sleegers, 2016).  
Besides the very low percentage of cases of autosomal dominant AD, the findings about APP, PS1 
and PS2 were used for the formation of the amyloid cascade hypothesis, which is the subject of the 
next section. 
 
1.1.2 The amyloid cascade hypothesis  
 
The mutations in APP and PS1/2 in cases of familial AD (FAD), and the higher risk of early onset of 
AD for Down syndrome patients led to the development of the amyloid cascade hypothesis 
(Ricciarelli and Fedele, 2017). As FAD patients will develop the same pathological changes as SAD 
patients, including tau aggregations, it was thought that Aβ aggregation is the initiator of AD (Musiek 
and Holtzman, 2015). However, later it was shown that accumulation and deposition of Aβ are not 
correlating with neuronal loss and cognitive decline. Additionally, it was observed via PET scan that 
many individuals have significant amyloid plaque burden without showing any symptoms of memory 
impairment (Delaere et al., 1990; Dickson et al., 1992; Aizenstein et al., 2008; Villemagne et al., 
2011). Furthermore, there is practically no neuronal cell death observed in APP or APP/PS1 mutant 
transgenic mice modelling FAD with APP related mutations (Ricciarelli and Fedele, 2017). On the 
other hand, it has been shown, that changes in the distribution patterns of NFTs, NTs and neuronal 
loss correlate with the severity of AD (Braak and Braak, 1991). Furthermore the reduction of 
endogenous tau in AD mouse models is able to protect them from Aβ-induced synaptotoxicity and 
memory deficits (Ittner et al., 2010; Leroy et al., 2012). These results let to the assumption, that Aβ 
aggregation leads to the aggregation of tau which than causes the actual symptoms of AD (Bloom, 
2014). However, there seems to be no temporal or regional correlation in the distribution of NFTs 
and Aβ plaques in AD patients. In fact the formation of tau tangles actually seems to precede the 
one of Aβ plaques while the distribution of NFTs correlates way better with the development of 
clinical symptoms (Price et al., 1991; Schönheit, Zarski and Ohm, 2004). Additionally a recent study 
showed that the amount of tau tangles, but not Aβ  deposits, predicts the rate of subsequent atrophy 
with the highest correlation of tau deposits and atrophy in younger patients (La Joie et al., 2020). 
 
Impressive preclinical evidence from experiments with AD mouse models as well as patient derived 
pluripotent stem cells indicates that tau pathology is able to progress independent from Aβ 
accumulation and downstream of factors like apolipoprotein E, the endocytic system, cholesterol 
metabolism and microglial activation (van der Kant, Goldstein and Ossenkoppele, 2020).  
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This is in line with the fact that immunotherapies which target Aβ have failed to halt dementia and 
only had a minor effect on tau pathology (Nicoll et al., 2006, 2019; Nakagami, 2019).  
Overall, the amyloid cascade hypothesis was not able to fully explain the pathomechanisms 
underlying AD, and the role of Aβ overproduction and deposition in FAD and SAD stays cryptically. 




Tau aggregates and builds deposits in neurons and glial cells in more than 20 disorders including 
AD, progressive supranuclear palsy (PSP), cortico basal degeneration (CBD), Pick's, disease (PiD), 
postencephalitic parkinsonism (PEP), and frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17) (Arendt, Jens T Stieler and Holzer, 2016)  These tauopathies have been 
distinguished into four different classes based on the ratio of the tau isoforms involved in their 
fibrillary lesions (table1). Some tauopathies contain only 3 microtubule binding repeats (3R), some 
contain 4 microtubule binding repeats (4R) and some contain both (3R and 4R) (see also 1.2.1).  
Most of these diseases occur sporadic (V M Lee, Goedert and Trojanowski, 2001; Virginia M-y Lee, 
Goedert and Trojanowski, 2001; Arendt, Jens T. Stieler and Holzer, 2016). While it was shown that 
tau dysfunction is clearly able to cause neurodegeneration, and some of the tauopathies show 
mutations of the tau gene MAPT (see also 1.2.2), it stays poorly understood via which mechanisms 
tau is involved in these neurodegenerative disorders (Arendt, Jens T. Stieler and Holzer, 2016). The 
clinical symptoms vary as well between the different tauopathies, depending on the affected brain 
regions (Williams, 2006). One of the most intriguing questions with high relevance for both, the 
physiological and pathophysiological function of tau in these context is the large heterogeneity of tau 
isoforms in the different tauopathies and the biological meaning of these different tau isoforms 






Table 1: Molecular classification of tauopathies according to the predominant tau isoform pattern.  
Based on the ratio of the 3R and 4R tau isoforms involved in the fibrillary lesions, four different classes of 
tauopathies have been distinguished (Arendt, Jens T Stieler and Holzer, 2016). 
 
1.2 Microtubule-associated protein tau (MAPT) 
 
1.2.1 Tau occurrence and isoforms 
 
Tau proteins belong to the family of the microtubule-associated proteins (MAPs) (Weingarten et al., 
1975) They are expressed  in many animal species comprising Caenorhabditis elegans (Goedert et 
al., 1996),  Drosophila (Cambiazo, González and Maccioni, 1995), rodents (Lee, Cowan and 
Kirschner, 1988), bovines (Himmler, 1989), goat (Nelson et al., 1996), monkeys (Nelson et al., 1996), 
and humans (Goedert et al., 1989; Nelson et al., 1996).  
In humans the tau gene is located on chromosome 17 at band position 17q21 (Neve et al., 1986). 
Tau is expressed in the brain in neurons, astrocytes and oligodendrocytes (Shin et al., 1991).  
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It is also expressed in neurons of the peripheral nervous system, skeletal and heart muscle tissue, 
skin, gastrointestinal tract, lung, kidney, ovary, pancreas, fibroblasts and lymphocytes (Iis, 1996; 
Thurston, Zinkowski and Binder, 1996; Miklossy et al., 1999; Pryor et al., 2002; Askanas and Engel, 
2008; Makrantonaki et al., 2012; Dugger et al., 2016).  
The human tau gene contains 16 exons (Andreadis, Broderick and Kosik, 1995). The primary 
transcript of tau contains 13 exons, as the exons 4A, 6 and 8 are not transcribed in human. The 
Exons −1 and 14 are transcribed, however not translated. Exons 1, 4, 5, 7, 9, 11, 12, 13 are always 
translated, while the exons 2, 3, and 10 are alternatively spliced. In consequence there are six 
different tau isoforms (figure1). These isoforms differ by the absence or presence of exon 2 and 3 in 
the amino-terminal part, in combination with either three or four repeat-regions (R1, R3 and R4 or 
R1–R4) in the carboxy-terminal part and absence or presence of exon 10 in the carboxy-terminal 
part. The shortest tau isoform (missing exon 2,3 and 10) is only found in the fetal brain and is 









Figure 1: Tau Isoforms 
The human tau gene is located over 100kb on the long arm of chromosome 17 at position 17q21. It contains 
16 exons, exon −1 is a part of the promoter (upper panel). The tau primary transcript contains 13 exons, since 
exons 4A, 6 and 8 are not transcribed in human (middle panel). Exons −1 and 14 are transcribed but not 
translated. Exons 1, 4, 5, 7, 9, 11, 12, 13 are constitutive, and exons 2, 3, and 10 are alternatively spliced, 
giving rise to six different mRNAs, translated in six different CNS tau isoforms (lower panel). These isoforms 
differ by the absence or presence of one or two 29 amino acids inserts encoded by exon 2 (yellow box) and 3 
(green box) in the amino-terminal part, in combination with either three (R1, R3 and R4) or four (R1–R4) repeat-
regions (black boxes) in the carboxy-terminal part. The fourth microtubule-binding domain is encoded by exon 
10 (slashed box) (lower panel). The adult tau isoforms include the longest 441-amino acids component 
(2+3+10+), the 410-amino acids component (2+3+10−), the 412-amino acids component (2+3−10+), the 381-
amino acids component (2+3−10−) and the 383-amino acids component (2−3−10+). The shortest 352-amino 








1.2.2 Tau Mutations 
 
Most tauopathies occur sporadic whiteout any detectable mutations as the cause of disease (Lee, 
Goedert and Trojanowski, 2001; Arendt, Jens T. Stieler and Holzer, 2016). Disease causing 
mutations of the tau gene MAPT are normally associated with FTDP-17 (Hutton et al., 1998; Poorkaj 
et al., 1998). Thus far  53 mutations causing FTDP‐17 have been found (Ghetti et al., 2015). The 
majority of the mutations are located between exons 9-13 in the microtubule- binding domain and in 
intron 10 (Rademakers, Cruts and Van Broeckhoven, 2004; Ghetti et al., 2015). Mutations between 
exons 9-13 predominantly lead to tau filament deposits in neurons. Mutations in intron 10 can cause 
tau deposition in neurons and glial cells (Ghetti et al., 2015). In addition to FTDP‐17, MAPT mutations 
have been found for some cases of Pick's disease, PSP, CBD, and GGT (Murrell et al., 1999; Hogg 
et al., 2003; Tacik et al., 2015). 
Due to an inversion polymorphism on chromosome 17q21.31 there are two haplotypes auf tau gene 
MAPT, MAPT H1 and MAPT H2. There are multiple H1 sub haplotypes but only one H2 haplotype 
(Stefansson et al., 2005). The H2 haplotype protects against PSP, while inheritance of H1 is a risk 
factor for PSP and CBD (Williams and Lees, 2009). However, there are no obvious pathogenic 
missense or splice site mutations in MAPT in the large majority of sporadic cases of PSP and CBD 
(Ghetti, Wszolek and Boeve, 2011). A direct connection between MAPT mutations and AD has not 
been proven so far.  
 
1.2.3 Tau functions 
 
Tau promotes the assembly and stabilization of microtubules (MTs) (Lee and Rook, 1992). It plays 
an important role in neurogenesis, axonal maintenance and axonal transport (Hernandez and Avila, 
2007). Tau is predominantly present in the cytoplasma but it can also be found  associated to the 
cell membrane and the nucleus (Arrasate, Pérez and Avila, 2000; Maina, Al-Hilaly and Serpell, 
2016). 
The functions of tau depend on the different tau domains.  
The N-terminal domain is involved in the regulation of MT dynamics by influencing the attachment 
between MTs and other cell components (Chen et al., 1992). It inhibits axonal transport in neurons 
(Kanaan et al., 2011) and influences the subcellular localization of tau (Liu and Götz, 2013; 
Paholikova et al., 2015). Additionally, the N-terminal region mediates the interaction of tau with the 
plasma membrane and different proteins like apolipoprotein A1, β-synuclein and synaptophysin 
(Brandt, Léger and Lee, 1995; Liu et al., 2016). 
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The proline-rich domain seems  to play a role in modulating the signaling functions of tau via binding 
of several protein kinases (Morris et al., 2011). Additionally, the proline-rich domain regulates the 
interaction of tau with DNA and RNA (Wang et al., 2006; Qi et al., 2015).  
Besides that the proline-rich domain is involved in the regulation of MT assembly and actin binding 
of tau (He et al., 2009; Maina, Al-Hilaly and Serpell, 2016).   
As the name suggests, the microtubule binding repeats (R1-R4) mediate the binding of tau at the 
microtubules. The flanking sequences, which separate the repeats from each other, play a regulatory 
role in this process (Mukrasch et al., 2007; Sillen et al., 2007). Other proteins which bind to the repeat 
domain are α-synuclein (Jensen et al., 1999), histone deacetylase 6 (HDAC6) (Ding, Dolan and 
Johnson, 2008), apolipoprotein E (Huang et al., 1995), PS1 (Takashima et al., 1998) and F-actin 
(Correas, Padilla and Avila, 1990). By binding F-actin and MTs through the repeat domain tau acts 
as an important molecular tether between the actin and microtubule cytoskeleton (Elie et al., 2015). 
Additionally, the repeat domain binds to lipid membranes, DNA and RNA (Wang et al., 2006; 
Georgieva et al., 2014; Qi et al., 2015). 
For the C-terminal region function and binding partners are not known.  
Besides tau there are some other MT associated proteins (MAPs) with structural and functional 
similarities like MAP2 and MAP4 (Mandelkow and Mandelkow, 1995; Dehmelt and Halpain, 2005). 
The MAP1 family shows some functional and structural parallels however differs in the MT binding 
structures (Halpain and Dehmelt, 2006).   
 
1.2.4 Post-translational modifications of tau 
 
In order to regulate the various functions of tau, a wide range of post-translational modifications are 
performed on this protein. These modifications include phosphorylation, truncation, isomerisation, 
glycation, nitration, addition of β-linked N-acetylglucosamine (O-GlcNAcylation), acetylation, 
oxidation, polyamination, sumoylation, and ubiquitylation (Martin, Latypova and Terro, 2011). An 






Figure 2: Post-translational modifications of tau. 
 
The coloured bars indicate the approximate sites of each modification on the largest human CNS tau isoform 
(2N4R, 441 amino acids) (Guo, Noble and Hanger, 2017). 
 
 
1.2.4.1 Tau phosphorylation 
 
The phosphorylation of tau is the most prominent tau modification, which was studied to the highest 
extent. This is due to the fact, that tau in NFTs is highly phosphorylated (Goedert et al., 1992). Tau 
comprises 85 potential phosphorylation sites, respectively 45 serine, 35 threonine, and five 
tyrosine residues (Hanger, Anderton and Noble, 2009). With phosphorylated tau in NFTs and the 
large number of potential phosphorylation sides it is no surprise, that tau phosphorylation has a 
big impact on its physiological function. The increase in tau phosphorylation under pathological 
conditions reduces its affinity towards MTs which results in destabilization of the cytoskeleton 
(Drewes et al., 1995). The detached tau itself undergoes self-aggregation resulting in tau oligomers 
and higher order tau aggregates (Kopke et al., 1993; von Bergen et al., 2000). Additionally, tau 
phosphorylation alters its interaction with the cytoplasmic membrane, DNA, Fyn and other binding 
partners, leading to a range of impaired signaling pathways (Hanger, Anderton and Noble, 2009). 
The phosphorylation and dephosphorylation of tau is regulated by different kinases and 
phosphatases (Avila, 2008). The kinases can be summarized in three broad groups: (a) proline-
directed protein kinases (PDPKs), which are serine/threonine kinases and include glycogen 
synthase kinase-3 (GSK-3), cyclin-dependent kinase-5 (Cdk5) and mitogen-activated protein 
kinases (MAPKs), (b) non-PDKs, which are serine/threonine kinases including cAMP-dependent 
protein kinase A (PKA), casein kinase 1 (CK1) and microtubule affinity-regulating kinases (MARKs), 
and (c) protein kinases specific for tyrosine residues including Src, Fyn, Abl, and Syk (Martin, 




The phosphorylation patterns of tau first led to the idea that individual kinases are modulating the 
functions of tau, however many residues are phosphorylated by different kinases and many kinases 
phosphorylate numerous different residues. The kinases GSK-3, cdk5, CK1 and PKA have been 
identified as important multi residue kinases for tau and were intensively studied as potential drug 
targets in AD (Hanger, Anderton and Noble, 2009). For the tau phosphatases, protein phosphatase 
2A (PP2A) is responsible for more than 70% of the cellular phosphatase activity in the brain (Liu, 
Grundke-Iqbal, et al., 2005).  PP2A dephosphorylates tau and seems to play a role in the regulation 
of tau phosphorylation (Gong et al., 2002). Additionally, the activity of PP2A is decreased by ca. 50% 
in AD brains (Liu, Grundke-Iqbal, et al., 2005). Protein phosphatase 5, (PP5), is another important 
phosphatase which dephosphorylates tau and is reduced in activity by ca. 20% in AD brains (Liu, 
Iqbal, et al., 2005).  
Together these findings show that hyperphosphorylation of tau is most likely the result of a 
disturbance in the complex interplay of various kinases and phosphatases in the brain.  
 
The permanent interplay of tau phosphorylation and dephosphorylation is also one of the main 
reasons why till today it is not well known which phosphorylation sites of tau are involved in the 
formation of tau pathogenesis and which sites are phosphorylated after the establishment of the 
pathology.  
 
1.2.4.2 Tau truncation 
 
The truncation of tau occurs under pathological and physiological conditions in various cells and 
brain tissues. Tau is the target of a huge variety of proteases such as caspases, calpains, thrombin, 
cathepsins and PSA (puromycin-sensitive aminopeptidase),  which cleave it at many distinct 
proteolytic sites (Hanger and Wray, 2010; Quinn et al., 2018). The role of tau fragmentation for 
neurodegeneration is still debated. Truncations of tau at position 421 by caspase3 and position 391 
by HTrA1 are associated with the formation of NFTs in AD (Basurto-Islas et al., 2008) and cleavage 
of tau by asparagine endopeptidase (AEP) is believed to promote tau pathology (Zhang et al., 2014). 
Contrary to these results, in samples from AD patients, full-length tau is the major component of the 
PHFs (Goedert et al., 1992) and in human mutant tau transgenic  P301S or P301L mice tau 
truncation at position 421 was only found in small amounts in the brain in a  late stage of the 
tauopathy (Lin, Dickson and Sahara, 2011; Zhang et al., 2014). In addition, overexpression of 
protease PSA inhibited tau induced neurodegeneration in tau transgenic P301L mice and Drosophila 
(Karsten et al., 2006; Kudo et al., 2011). Mice overexpressing a wild-type 3R tau fragment from 
amino acid 151-421 (Δtau) only showed a mild phenotype. However, mice expressing Δtau 
together with full length tau developed severe neurotoxicity.  
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This toxicity was reversible via halting the expression  of Δtau and only oligomers of tau but no 
fibrils were detected in the affected mice (Ozcelik et al., 2016). 
 
1.2.4.3 Tau acetylation 
 
The acetylation of tau occurs via cAMP-response element binding protein (CREB)-binding protein 
(CBP) (Min et al., 2010) and via auto-acetylation (Cohen et al., 2013). Tau deacetylation is mediated 
by sirtuin 1 (SIRT1) and HDAC6 (Cook et al., 2014). CBP acetylates tau at several lysine residues 
located in the MT binding repeats and the proline-rich region, auto-acetylation occurs preferentially 
at lysine residues located in the MT binding repeats (Cohen et al., 2016). Tau acetylation at 
different positions is proposed to be responsible for both, protection from AD and to be involved in 
the development of AD and other tauopathies.  
Acetylation of the tau lysine residues 259, 290, 321 and 353 is reduced in AD brains compared to 
healthy controls. Acetylation at these residues seems to protect tau from increased 
phosphorylation and decreases tau aggregation (Cook et al., 2014).  
On the other hand, acetylation of tau at lysines 174, 274 and 280 was found in the post-mortem 
brains of AD, PiD, PSP and frontotemporal lobar degeneration-tau (FTLD-tau) patients, and is 
supposed to be pathological (Irwin et al., 2013; Min et al., 2015). How the pathological changes in 
tau acetylation occur and if they can be corrected is still unknown and could be a potential starting 
point for the development of new treatment strategies against AD.  
 
1.2.4.4 Tau glycosylation 
 
N-glycosylation of tau was only found in AD brains but not in healthy controls (Wang, Grundke-
Iqbal and Iqbal, 1996). It is suggested, that N-glycosylation contributes to tau hyperphosphorylation 
by facilitating phosphorylation and suppressing dephosphorylation (Liu et al., 2002). Why and how 
it comes to N-glycosylation of tau in AD is unclear.  
O-linked N-acetylglucosamine (O-GlcNAc) occurs at serine and threonine residues and might 
protect against tau phosphorylation, as it takes place at the same amino acids (Liu et al., 2004). It 
additionally seems to reduce tau aggregation without changing its ability to bind and to stabilize 
microtubules (Yuzwa et al., 2014). It has also been shown, that tau O-GlcNAcylation and the 
activity of the responsible protein O-GlcNAc transferase are reduced in the brain of AD patients 
(Liu et al., 2004; Wang et al., 2016). Therefore, O-GlcNAc regulation could be a promising target 
for potential AD therapy. 
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For the remaining post-translational modifications, the relevance for tau function and toxicity is not 
well investigated by now. 
Deamination of tau at asparagine residue 279 (N279) takes place in AD at the 4-repeat isoform, 
but not in CBD or PSP, and might reduce the ability of tau to bind MTs (Dan et al., 2014). 
Tau isomerization by Pin1 seems to play a role in tau dephosphorylation at Thr231, and Pin1 
dysfunction might play a role in tau pathology (Hamdane et al., 2006). 
Tau nitration caused by nitrative injury could be involved in the development of filamentous tau 
inclusions (Horiguchi et al., 2003). 
Glycation of tau, in postmortem samples from AD patients, was found at lysine residues with a 
preference for lysine residues inside the MT binding repeats. This might have an effect on the MT 
binding ability of tau (Ledesma, Bonay and Avila, 1995). 
Tau ubiquitination is regulated by the ubiquitin ligase CHIP, which directly interacts with the heat 
shock proteins Hsp70/90. Therefore, CHIP leads to tau degradation via ubiquitination. However, 
CHIP also increases tau aggregation (Petrucelli et al., 2004). Interestingly 73% of the lysine 
residues targeted by ubiquitination are also the target of acetylation, indicating an interplay of 
acetylation and ubiquitination in tau regulation (Morris et al., 2015).  
Tau sumoylation has its mayor target site at lysine 340 and counteracts the effects of 
ubiquitination, while reciprocally stimulating tau phosphorylation, at least in cell culture (Luo et 
al., 2014).  
Tau methylation occurs on lysine and arginine residues. The lysine methylation seems to occur 
predominantly in the microtubule-binding repeat region and potentially has an effect on tau MT 
binding and tau aggregation (Yang and Seto, 2008; Funk et al., 2014). 
These results show that there are at least four tau modifications which potentially compete for 
lysine residues (glycation, acetylation, ubiquitination, and methylation). This indicates a strategic 
role of lysine modification when modifying tau function. 
 
Altogether there are many post-translational modifications of tau, which can be present under 
physiological and / or pathological conditions and can take place at various sites of tau mediated by 
a variety of enzymes. This huge amount of variables makes it very difficult to identify which post-
translational modifications of tau have the highest impact on health and disease and would be the 





1.2.5 Murine tau 
 
The longest isoform of tau in mice and humans has an identity of 89% in the amino acid sequence 
(Hernández, Merchán-rubira and Vallés-saiz, 2020). The biggest difference between human and 
murine tau are the N-terminal residues  17 to 28 which are present in human but not in murine tau, 
the MT binding repeats on the other hand only differ by three amino acids (Hernández et al., 2019). 
In mouse brain the composition of tau isoforms transitions from the smallest tau isoform (3R‐0N) in 
the fetal brain to a mixture of three 4‐repeat isoforms (4R‐0N, ‐1N, ‐2N) in the adult brain (Kampers 
et al., 1999). In vitro murine tau assembles into Alzheimer‐like PHFs with a similar efficiency than 
human tau (Kampers et al., 1999). The formation of murine tau fibrils can be induced by 
hyperphosphorylation and the resulting fibrils resemble the ones obtained by hyperphosphorylation 
of human tau (Chohan et al., 2005).  However in vivo, mice expressing mTau never develop NFTs 
even when endogenous mTau is overexpressed (Adams et al., 2009).  
 
1.3 Prions and the prion-like properties of tau 
 
The word prion is derived from proteinaceous and infectious (Prusiner, 1982). Prion diseases (PDs) 
can occur as genetic, infectious or sporadic disorders. Creutzfeldt-Jakob disease (CJD) shares most 
symptoms of a progressive dementia, while scrapie of sheep and BSE can be described as ataxic 
illnesses (Hope et al., 1988). All PDs in mammals involve modifications of the prion protein (PrP), a 
small, cell-surface glycoprotein, which is expressed under physiological conditions in mammalian 
cells (Prusiner, 1991). PrP becomes misfolded and aggregates into β-sheet structured amyloid 
(PrPSc) (Scheckel and Aguzzi, 2018). Tau also develops β-sheet structured amyloids which spread 
throughout the brain in a specific fashion that is distinct for each tauopathy (Arnold et al., 2013).  
Prions spread by forcing their pathological conformation on physiologically folded proteins, thereby 
transforming them to new prion proteins. The prion spreading seems to appear in a circle of 
nucleation and fragmentation and can be induced via the introduction of misfolded protein as seeds 





Figure 3: The pathological pathway leading from soluble proteins to insoluble filaments 
The formation of pathological seeds is a rare and energetically unfavorable event. Once a seed has formed, 
single molecules can change shape and join the growing aggregates. Seed addition induces rapid assembly 
of the soluble protein. Fragmentation generates new seeds, accelerating the formation of aggregates. 
Filaments represent the endpoints of aggregation (Goedert, 2015). 
 
In case of tau, seeding with different tau seeds leads to the formation of fibrils with different 
conformations. These fibrils are able to keep their specific conformations and biochemical properties 
throughout several passages in vivo as well as in vitro (Kaufman et al., 2016). Other proteins which 
can be seeded in a pathological conformation and then spread through the brain are the second 
hallmark protein of AD Aβ and α-synuclein in Parkinson disease (Musiek and Holtzman, 2015; Kim 
et al., 2019). While these proteins share the same mechanisms of misfolding and propagation their 
infectivity seems to be lower than the one of PrP. Therefore the term prionoids has been proposed 







1.3.1 Yeast prion Sup35 as a potential tau seed 
 
The most simplistic eukaryotes in which prions occur are yeast, which are single cell organisms. The 
yeast prion that was first discovered and most studied is Sup35 (Wickner, 1994). It is composed of 
3 sequence elements (Paushkin et al., 1997), a N-terminal (N), a middle (M) and a C-terminal (C) 
domain (Lindquist et al., 2004). In yeast Sup35 acts as a translation termination factor, which reacts 
to a lowering of the pH via liquid-like phase separation and the formation of reversible protective 
gels. This process is regulated via the N domain of Sup35 (Franzmann et al., 2018). Prion forms of 
Sup35, called [PSI+], are found in many wild yeast strains and in Saccharomyces cerevisiae strains 
of  commercial baker’s yeast, brewery yeast and dry wine yeast (Halfmann et al., 2012; Kelly, Busby 
and Wickner, 2014). Like tau and PrP, Sup35 aggregates into β-sheet structured amyloid. The N 
and M domain are sufficient to form Sup35NM fibrils harboring prion properties (Gorkovskiy et al., 
2014). Sup35 prions as well show the remarkable stability observed in prion amyloid assemblies of 
prions like PrP, which enables them to survive the transfer from one organism to another (Halfmann 
et al., 2012; Walker et al., 2013). Furthermore, the Sup35NM domain was shown to propagate as a 
prion in mammalian cells (Krammer et al., 2008). Tau and Sup35 are both intrinsically soluble, 
disordered and unfolded proteins, which can form highly ordered β-sheet structured amyloid 
aggregates closely resembling each other in case of tau and Sup35 fibrils composed of fibril-forming 
segments from the respective protein (Sawaya et al., 2007; Mirbaha et al., 2018; Ohhashi et al., 
2018). In this context it is interesting to mention, that long before the knowledge of prionoids and the 
transcellular spreading of tau it was proposed, that an infectious agent enters the cranium and brain 
from the nasopharyngeal cavity and spreads from there via the structures closely linked with each 
other by neuronal pathways (Ulrich, 1985). Additionally, in a recent article it was shown, that gut 
injection of α-synuclein fibrils leads to the conversion of endogenous α-synuclein to a pathological 
form which travels to the brain via the vagus nerve and causes features of Parkinson disease (Kim 
et al., 2019).  
Based on these discoveries and in light of the recently growing understanding of the human 
microbiome (Gilbert et al., 2016) it is desirable to investigate if an archaic natural yeast protein like 








1.3.2 Other yeast prions 
 
Ure2 is another yeast prion which is able to build amyloid fibrils in vivo and in vitro and plays an 
important role in nitrogen catabolism (Baxa et al., 2002). The prion form of Ure2 is unable to block 
the uptake of ureidosuccinate therefore delivering a route for the synthesis of Uracil in environments 
lacking this important nucleobase (Wickner, 1994). Other than Sup35 aggregates, Ure2 oligomers 
and fibrils are toxic to mammalian cells (Pieri et al., 2006). Interestingly Ure2 and Sup35 do not show 
amino acid identity with each other or with mammalian PrP (Tuite, 2000). While the prion-forming 
domains of both proteins do not share significant amino acid sequence identity they do share an 
atypically high proportion of the polar amino acids Gln and Asn, which contain uncharged R groups, 
as well as an overall low charge content  (Tuite, 2000). Another yeast prion with a Gln+Asn-rich 
prion-forming domain is Rnq1. While the function of the Rnq1 prion [RNQ+] in Saccharomyces 
cerevisiae is unknown [RNQ+]  is able to promote the formation of the Sup35 prion besides being 
completely non-homologous (Derkatch et al., 2004; Westergard and True, 2014). It was therefore 
hypothesized that [RNQ+] primes the cell for the formation of the Sup35 prion in order to induce it in 
conditions where Sup35 prion formation can be advantageous (Westergard and True, 2014). 
Together this data shows the existence of a variety of prions in yeast which highly defer in their 
respective DNA sequence. This gives evidence that structural similarities are more important for 
prion seeding than similarities in the DNA assembly.  
 
1.3.3 Prions in bacteria, plants and viruses 
 
Besides mammals and yeast, prion proteins have also been discovered in bacteria, plants and 
viruses (Chakrabortee et al., 2016; Pallarès, Iglesias and Ventura, 2016; Yuan and Hochschild, 
2017; Nan et al., 2019). For bacteria it was discovered that the protein curli, which is expressed by 
E. coli and other Enterobacteriaceae, aggregates and builds amyloid fibers which are a central 
component of their extracellular matrix and therefore play a key role for their environmental 
persistence (Chapman et al., 2002; Smith et al., 2017). Additionally, the Rho termination factor of 
Clostridium botulinum (Cb-Rho) contains a prion-like domain with an amyloidogenic core, which 
enables Cb-Rho to form amyloid fibrils (Pallarès, Iglesias and Ventura, 2016; Yuan and Hochschild, 
2017).  
For plants the prion-like domain of Arabidopsis protein Luminidependens (LDPrD) was able to form 
higher-order oligomers and was capable of replacing the prion-domain functions of Sup35 in yeast 




For viruses, protein LEF-10 behaves as a prion in Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV), a large double-stranded DNA virus that infects insects. In case of 
high multiplicity of infection in virus-infected cells LEF-10 can change its conformation to an 
aggregated state, which leads to the inhibition of viral late gene expression (Nan et al., 2019).  
These findings underline the far-reaching prevalence of prion proteins in living organisms from many 
different species. Furthermore, these results suggest, that the development of prions happened a 
very long time ago as these mechanisms are so widespread in nature.  
 
1.4 Prion-like behavior of tau in animal models for tauopathies  
 
1.4.1 Induction of tau aggregation by expression of mutated tau 
 
Several mouse lines were developed with the aim to study tau pathology in vivo. These mouse lines 
express human tau (htau) that carries MAPT mutations associated with FTDP-17 like G272V, P301L, 
P301S, V337M and R406W (Frank, Clavaguera and Tolnay, 2008). In contrast to mice which 
express wild type (WT) htau most of these mice, expressing pathological tau mutants, develop NFTs 
and NTs several months after birth. Additionally, these mice develop neuronal cell loss which 
manifests in motoric and cognitive impairments.  
One of these mouse models which was extensively studied is the P301S htau mouse model (P301S 
mouse) (Allen et al., 2002). P301S mice express the shortest 4R htau isoform (0N4R, 383 aa) 
comprising the P301S mutation (proline replaced by serine at position 301 of the amino acid 
sequence). The expression of the P301S transgene is controlled by the thy-1.2 promoter which has 
the highest expression rates in neurons of the brain stem and the spinal cord. The overexpressed 
P301S tau in these mice is hyperphosphorylated and fibers can be found in nerve cells in brain and 
spinal cord. Homozygous mice show a 49% reduction in the number of motor neurons of the spinal 
cord, likely being the main cause for the paraparesis, muscle weakness and tremor that mice develop 








1.4.2 Induction of tau aggregation by inoculation of seeds 
 
The development of NFTs can be induced by intracerebral injection of tau seeds (Clavaguera et al., 
2009). The injection of Alz17 mice, which express the longest human tau isoform and do not exhibit 
filamentous tau aggregates (Probst et al., 2000), with brain homogenates of P301S mice containing 
tau fibrils, leads to tau aggregation spreading from the injection site (Clavaguera et al., 2009). After 
the injection the Alz17 mice developed hyperphosphorylated htau, NFTs and NTs and coilded-bodies 
in a progressive manner. The depletion of the homogenates from htau abolished this seeding effect. 
The induced changes of tau confirmation spread to connected brain regions with an increase in 
reach over time and a higher spreading radius for hyperphosphorylated htau compared to NFTs and 
NTs. It is important to note, that the injected Alz17 mice did not develop neuronal loss or any of the 
motoric impairments present in old P301S mice. The lack of motoric impairment most likely comes 
from the fact that the fibrils were inoculated in the hippocampus of the mice (Clavaguera et al., 2009) 
while motoric problems result from the death of neurons in brain stem and spinal cord (Allen et al., 
2002). As tau spreading is a slowly advancing process and the hippocampus is only remotely 
connected to the brain stem the mice likely just dye of old age before the spread of tau aggregation 
reaches the brain stem. This estimation is in accordance with the fact, that in cases where human 
patients where accidently infected with  PrPSc or Aβ, by contaminated growth hormones, it took an 
incubation time exceeding 30 years until neurodegeneration was observed (Jaunmuktane et al., 
2015; Purro et al., 2018).  In another seeding trial injection of presymptomatic 2 months old P301S 
mice with brain homogenate of symptomatic P301S mice led to accelerated tangle formation with 
increased density of hyperphosphorylated htau (Ahmed et al., 2014).  
Besides mouse derived tau fibers, tau extracts from AD patients and tau filaments generated in vitro 
also have the ability to induce hyperphosphorylation and aggregation of tau in different mouse 
models (Clavaguera et al., 2013; Sanders et al., 2014; Kaufman et al., 2016). The brain 
homogenates from post mortem patient biopsies of various tauopathies including AD have the ability 
to induce the aggregation of WT htau in Alz17 mice.  
Remarkably filaments formed in the brains of the injected mice have the same confirmation as the 
tau fibers from the respective tauopathy patients. Furthermore, tau aggregates collected from mice 
seeded with patient samples and reinjected in new mice, again have the same structure as the 
original tau structures observed in the respective tauopathy patients (Clavaguera et al., 2013). In 
vitro generated tau fibers as well kept their specific conformation when seeded and reseeded for two 
times. This was the case for seeding in mice via brain injection as well as for in vitro seeding in cells 
(Sanders et al., 2014).  
On top of that the generation of very distinct tau fibers in vitro and their injection in mutant tau 
expressing P301S mice resulted in a strain specific progression and spreading of tau pathology.  
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The P301S mice showed different progression rates and different affected brain regions concerning 
abnormal tau phosphorylation (Kaufman et al., 2016). 
 
1.5  Cryo-EM structure of tau filaments from AD, Pick’s disease, 
Chronic traumatic encephalopathy (CTE) and CBD 
 
In recent years, scientist have been able to resolve the structures of various tau filaments from 
different tauopathies. They  discovered that PHFs and straight fibrils of tau had the same C-shaped 
protofibril structure in post mortem samples of an individual with AD (Fitzpatrick et al., 2017). The 
filaments of Pick’s disease tau consist of residues Lys254–Phe378 and are folded differently than 
the filaments in AD (Falcon et al., 2018). 
The observed structure of tau folding in tau from a post mortem Pick’s disease patient explained the 
selective aggregation of 3R tau and the difference in phosphorylation compared to the tau filaments 
found in the samples of an AD patient (Falcon et al., 2018). In CTE, similar to AD, 3R and 4R tau 
aggregate in order to form C-shaped protofilaments (Falcon et al., 2019). In CBD tau filaments 
consist only of 4R tau. CBD fibrils were analyzed by to different groups of scientist, (Zhang et al., 
2019; Arakhamia et al., 2020), both groups found in essence the same β-sheet configuration and 
fold for CBD fibrils. Zhang additionally detected a molecule inside the fold of the protofibril which was 
not covalently bound and has an estimated negative net charge. Arakhamia on the other hand found 
post translational modifications (PTMs) of CDB fibrils via mass spectrometry. Interestingly this 
analysis showed that acetyl and ubiquitin groups predominated in the fibril-forming core of the fibril. 
If the hydrophilic molecule detected inside the fold of the tau fibril or the PTMs of CDB tau play a role 
in the folding, and therefore the confirmation, of these tau fibrils still needs to be investigated. For 
the latter it would be possible to remove PTMs from tau fibrils before using them as seeds and to 
compare the conformation of the resulting fibrils with the one of fibrils which were seeded by the use 
of tau seeds containing PTMs. 
Together these results suggest that the different tau confirmations specific for different tauopathies 
play a crucial role in the progression of pathology and the brain areas which are affected by the 






1.6 Neurotoxicity of tau oligomers in the absence of tau fibrils in a 
murine tauopathy model 
 
Native tau is a soluble and unfolded protein acting as a microtubule stabilizer in neuronal cells. 
Previous research suggests, that different modifications of tau including phosphorylation, 
fragmentation, and conformational changes, can induce filamentous tau aggregation (Sahara, 
Maeda and Takashima, 2008). This aggregation starts with the formation of oligomeric species and 
subsequent aggregation into fibrils, culminating in the formation of tangles. Tau aggregation can 
spread towards anatomically connected regions in a prion-like manner (Clavaguera et al., 2009; 
Goedert, Eisenberg and Crowther, 2017). In our lab it was recently shown that tau toxicity can be 
mediated by oligomeric tau species (Ozcelik et al., 2016). 
If heterozygous P301S mice are crossed with Tau62 mice, expressing the 3R tau151–421 (Δtau) 
fragment, the co-expression of full-length P301S mutant tau with Δtau in 3-weeks-old P301SxTAU62 
transgenic mice leads to the formation of soluble high molecular weight tau oligomers. These 
oligomers are sufficient to cause extensive nerve cell dysfunction and severe motor palsy in the 
absence of insoluble tau aggregates and neurofibrillary tangles (NFT) (Ozcelik et al., 2016). 
Strikingly, once the doxycycline-inducible expression of Δtau is switched off in these mice, their 
severe phenotype reverses within 3 weeks, and animals regain their motor competence, even though 
heterozygous P301S mutant tau expression is maintained (Ozcelik et al., 2016).   
 
1.7 The human microbiome  
 
The human body has co-evolved with trillions of microbes which build ecosystems specific for the 
body site they inhabit. These communities are collectively referred to as the human microbiome 
(Methé et al., 2012). As the relationship between microbiota and the host organism has been formed 
during a long process of co-evolution it is in general symbiotic (Bäckhed et al., 2005; Littman and 
Pamer, 2011).  
Changes in the composition of the microbiota can lead to dysbiosis, which is associated with several 
diseases such as type 1 and type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease 
and inflammatory bowel disease (Zhang and Zhang, 2013; Nagpal, Yadav and Marotta, 2014; Palm, 





This negative deviation in the gut often leads to the overgrowth of pathogenic bacteria or fungi 
accompanied with a loss of microbial diversity and an inflammatory response by the host that 
involves the induction of inflammation mediating T-helper cells like Th1 and Th17 cells (Gaboriau-
Routhiau et al., 2009; Ivanov et al., 2009).  
Microbiomes often differ to a large degree between different individuals even in the absence of a 
disease (Huttenhower et al., 2012). The reasons for this interpersonal diversity are mainly 
unexplained so far, although diet, environment, host genetics and early microbial exposure seem to 
play a certain role (Qin et al., 2010; Huttenhower et al., 2012). Even shared types of bacteria differ 
by more than an order of magnitude between healthy individuals (Turnbaugh et al., 2007; 
Huttenhower et al., 2012). Therefore, it became clear, that it is not practicable to define an ideal set 
of specific microbes as the composition of a healthy microbiome (Bäckhed et al., 2012; Shafquat et 
al., 2014). Which circumstances are necessary to enable the establishment and maintenance of a 
healthy microbiome still has to be investigated.  
 
1.7.1 The potential role of the microbiome in neurodegeneration 
 
The walls of the gastrointestinal tract are innervated by intrinsic and extrinsic neurons regulating 
many of the functions of the gut. For that reason, the brain is directly connected to the gut via 
parasympathetic extrinsic neurons in the brainstem and sacral spinal cord which run through the 
vagus and pelvic nerves (Uesaka et al., 2016). Therefore, Braak and coworkers formed the 
hypothesis, that the initial induction of α-synuclein aggregation is caused by a yet unknown agent in 
the gut which enters the brain via the vagus nerve (Braak et al., 2003).  Indeed, in Parkinson the 
same α-synuclein deposits are found in the gut and in the brain (Braak et al., 2004). Additionally, it 
was shown, that in mice exogenous misfolded α-synuclein in the gut leads to misfolded α-synuclein 
in the brain via the vagus nerve (Kim et al., 2019). However, the results from Parkinson patients are 
less clear, while a Swedish study found a small protective effect for vagus nerve dissection starting 
5 years post-surgery (Liu et al., 2017) a Danish study on the same topic was not able to find any 
significant difference between patients and controls with an intact vagus nerve (Tysnes et al., 2015). 
This suggests, that the vagus nerve is not the only route which can be used by α-synuclein in order 
to enter the brain. In line with this Braak and coworkers proposed a dual hit theory, proposing that a 
neurotropic pathogen enters the brain via the nose and gut. They suggested the initial process to be 
nasal. The pathogen is then swallowed in saliva and mucus, which allows it to cross the stomach 
wall and to invade the distal fibers of the vagus nerve, damaging the vagal dorsal motor nucleus in 




Simultaneously, the pathogen invades the brain from the nasal mucosa spreading via the olfactory 
bulb and anterior olfactory nucleus into the olfactory structures of the temporal lobe (Hawkes, Tredici 
and Braak, 2009). In line with this theory, researchers were able to show that injection of α-synuclein 
fibers into the olfactory bulbs of WT mice results in olfactory deficits and a spreading of α-synuclein 
which is reminiscent of the pattern observed in early stages of Parkinson (Rey et al., 2016). For more 
information about the nasal microbiome and its potential role in the development of 
neurodegenerative diseases see the text below “The nasopharyngeal microbiota”. 
Parkinson patients have an altered microbiome compared to healthy people with a higher presence 
of pro-inflammatory bacteria (Keshavarzian et al., 2015). E. coli are able to produce extracellular 
amyloid fibers called curli which play a role in the colonization of inert surfaces and the formation of 
biofilms (Chapman et al., 2002). In line with these results, in a recent study, scientists were able to 
show that gastrointestinal exposure of mice overexpressing human α-synuclein to bacterial amyloid 
protein curli leads to increased α-synuclein aggregation in the gut and the brain of those mice 
(Sampson et al., 2020). Additionally, intravenous injections of curli were able to accelerate amyloid 
protein A amyloidosis in a mouse model (Lundmark, Westermark and Olse, 2005). An even more 
potent acceleration of A amyloidosis was achieved by injections of Sup35 fibrils from  
Saccharomyces cerevisiae (Lundmark, Westermark and Olse, 2005). This is additional evidence for 
the ability of microbiome derived proteins to influence the aggregation of human amyloid formation.  
Oral bacteria may also produce amyloid proteins and mutants of the oral symbiont Streptococcus 
seem to be associated with cerebral micro bleeds (Tonomura et al., 2016). Infection of the oral cavity 
could thereby allow access to the trigeminal nerve and therefore a connection to the brain (Dando 
et al., 2014). 
 
1.7.2 The nasopharyngeal microbiota 
 
The nasopharyngeal cavity is densely colonized by a broad variety of microorganisms, many of them 
are commensals, however the nasopharyngeal cavity is also an anatomical reservoir for pathogenic 
microbes (Garcia-Rodriguez, 2002). Under certain conditions theses microbes are able to spread to 
the lower and upper respiratory airways where they cause respiratory infections, or invade the 
bloodstream, which can lead to sepsis and meningitis (Perez-Losada, A. Crandall and J. Freishtat, 
2016; Teo et al., 2016). The nasal sensors are in close contact to the microbiome in the 
nasopharyngeal cavity and they are anatomically connected with the limbic system, which is also 
affected early in AD (Ulrich, 1985).  
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This opens the possibility, that substances like prions from the nasopharyngeal microbiome could 
travel to the brain via the nasal sensors where they interact with prion like proteins like tau and 
therefore influence the development of neurodegenerative diseases including AD. 
Despite this information and other data about the incidence, prevalence and density of potential 
pathogens in the  nasopharyngeal cavity microbiota of children and adults, the detailed composition 
of the  microbial community in the nasopharyngeal cavity has not been studied yet  during health or 
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Understanding the mechanism provoking tau aggregation in Alzheimer’s disease (AD) and other 
neurodegenerative conditions remains an unmet challenge. We observed that a yeast prion can 
seed tau protein aggregation. This finding should prompt research efforts aimed at exploring 
potentially pathogenic roles of non-mammalian prions in neurodegeneration. 
Background  
AD patient-derived or synthetic tau aggregates can seed unfolded tau into β-sheet structured 
amyloid in a prion-like manner. Tau can also be cross-seeded by other neurodegenerative prion-like 
proteins including amyloid-β and -synuclein. Whereas prions have recently been discovered in a 
wide range of organisms including bacteria and plants, it remains unclear, whether such non-
mammalian prions can cross-seed tau aggregation.  
New/Updated Hypothesis 
We hypothesize that non-mammalian prions showing similar β-sheet structure as tau aggregates 
can seed tau aggregation. Such prions might serve as a pathogenic factor in sporadic tauopathies, 
including AD. In our present study, the yeast Sup35NM prion domain promoted the formation of 
morphologically distinct tau fibril strains in vitro. In vivo, hippocampal inoculation of Sup35NM fibrils 
accentuated tau pathology in P301S tau transgenic mice, providing first evidence for heterotypic 
cross-species seeding by a non-mammalian prion.  
Major Challenges for the Hypothesis 
While our study demonstrates seeding of a neurodegenerative prion-like protein by a yeast prion, it 
remains to be investigated whether such cross-species cross-seedings have any role in the context 
of neurodegenerative conditions such as AD. Future work should therefore explore potential 
heterotypic cross-seeding of tau by non-mammalian prions, including bacterial and plant prions. In 
parallel, cross-seeding of AD associated amyloid-β by non-mammalian prions should be assessed. 
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Algorithm-based screenings for microbiome-associated non-mammalian prions should be 
intensified. Eventually, clinical studies should explore the presence of such prions in AD patients.  
Linkage to Other Major Theories 
Template-based seeding as a nucleation-dependent process in prion aggregation has initially been 
described by Jarrett and Lansbury. We here extend this concept towards cross-species cross-
seeding of seemingly unrelated proteins with prion-like capacities in the context of AD. Our 
hypothesis builds on previous theories suggesting that in neurodegenerative diseases including AD, 
an exogenous pathogen might enter the brain via the olfactory system to trigger neurodegeneration.   
Keywords 




This article proposes that non-mammalian prions can be involved in the induction of pathological tau 
aggregation. This proposition is based on our observation that the yeast prion domain Sup35NM can 
seed fibril formation of the human tau protein in vitro as well as in vivo. Our finding provides initial 
evidence that archaic prions may play a role in the not yet understood pathogenesis of Alzheimer’s 
disease (AD) and other tauopathies. Tau protein aggregation in AD might, amongst other 
mechanisms, be provoked by non-mammalian prions present in the human microbiome or ingested 
from the outside, from where they may reach the central nervous system via the olfactory and/or 
vagal nerves.  
 
2. Background  
2.1. Historical evolution 
Tau is a natively unfolded microtubule-binding protein involved in axonal and nucleocytoplasmic 
transport, and in translation regulation. In AD, tau is hyperphosphorylated and eventually forms 
intraneuronal inclusions [1]. Besides AD, neuronal or glial tau aggregates are characteristic for more 
than 20 diseases, summarized under the term tauopathies [1]. The process of tau aggregation via 
the self-assembly of intrinsically disordered tau into highly ordered β-sheet-rich amyloid remains only 
partly understood, but is thought to be similar for all tauopathies [2]. In recent years, scientists have 
been able to resolve the structures of various tau filaments from different tauopathies. They 
discovered that paired helical filaments and straight fibrils of tau had the same C-shaped protofibril 
structure in post mortem samples of an individual with AD [3]. Of the tauopathy filaments examined 
so far, the tau folds of chronic traumatic encephalopathy (CTE) and AD are most similar to each 
other [3, 4]. In contrast, tau filaments derived from Pick’s disease patients were found to be folded 
differently [5].  
Similar to other aggregating proteins involved in neurodegenerative diseases, tau has prion-like 
properties [3, 5, 6]. Structural transformation of soluble proteins into their prion state is generally 
accompanied by an increase in β-sheet structure [7]. The template-based induction of β-sheet 
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structure in amyloidogenic proteins is referred to as “seeding” [8]. AD patient-derived or synthetic 
tau aggregates can seed unfolded tau into -sheet structured amyloid [1]. Seeding of tau protein 
monomers can also be provoked by β-sheet structured aggregates of heterologous proteins - a 
process known as heterotypic or cross-seeding [9, 10]. Seeding and cross-seeding are both thought 
to require similar folding and binding characteristics of the partnering proteins [11, 12]. Whereas tau 
aggregates often occur in parallel with aggregates of heterologous β-sheet structured prion-like 
proteins, e.g. amyloid-β in AD, -synuclein in Parkinson’s disease, and huntingtin in Huntington’s 
disease [13], the reasons for these mixed pathologies are not yet fully understood. While factors 
such as inflammation, disturbed cellular metabolism and others might be involved, cross-seeding of 
tau has been demonstrated for several prion-like proteins, including α-synuclein [14-17], amyloid-β 
[9, 18], and islet amyloid polypeptide (IAPP) [19]. 
2.2.  Rationale 
The vast majority of tauopathies, including AD, are sporadic diseases. In these disorders, the initial 
factor provoking the conversion of unfolded tau into β-sheet structured aggregates remains 
unidentified [1]. Here, we propose that, besides other factors, non-mammalian β-sheet structured 
protein templates might serve as initial seeds provoking tau aggregation in sporadic tauopathies.  
β-sheet structured amyloids are not only associated with a wide variety of neurodegenerative 
disorders, but they also occur in all forms of life. More than a dozen proteins which form β-amyloid 
structured prions have been found in fungi [7]. Recently, prions have also been discovered in 
bacteria [20-22], plants [23, 24], and even in the form of a viral expression factor [25]. The discovery 
that prions are widely present in nature and show structural similarities with human prion-like proteins 
like tau opens up the perspective that heterotypic seeding by non-mammalian prions might play a 
role in the pathogenesis of neurodegenerative diseases. Therefore, we decided to analyze, as a 
proof of concept, whether an archaic natural yeast prion would be able to seed human tau protein. 
For several reasons, we chose the yeast Sup35 prion to study the tau cross-species cross-seeding 
capacity of a non-mammalian prion. First, Sup35 prions form a parallel in-register β-sheet structured 
amyloid similar to tau aggregates [26]. Second, several yeast prions are known to promote the 
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aggregation of other yeast prions, suggesting heterogeneous seeding competence [27, 28]. 
Moreover, Sup35NM was shown to accelerate amyloid formation in a murine model of silver nitrate-
induced serum amyloid A amyloidosis [29]. Third, Sup35 is a naturally occurring prion, so far 
detected in wild yeast on grapes, in strains of commercial dry wine yeast [30], and in yeast samples 
from breweries and commercial fruits [31].  
Sup35 is the yeast prion first discovered and most studied [32]. The combined N-terminal (N) and 
middle (M) domains of Sup35 are sufficient to form Sup35NM fibrils with prion properties [33]. Similar 
to tau, Sup35 is involved in phase separation [34, 35]. Sup35NM is highly aggregation prone and 
only stays monomeric when purified in denaturing conditions, which require a high concentration of 
reducing agents [36-39]. Therefore, recombinant tyrosine-deleted Sup35NM protein (-
5TyrSup35NM), previously described as less aggregating [32], was used as a non-aggregated 
seeding control for our in vitro and in vivo seeding experiments. 
3. New or updated hypothesis  
We hypothesize that non-mammalian microbiotic or nutritional prions might, amongst others, serve 
as an aggregation-inducing pathogenic factor in sporadic tauopathies, including AD. As a proof of 
concept, we aimed for cross-seeding of human tau protein by a yeast prion domain in vitro as well 
as in a tau transgenic mouse model.  
3.1.  Early experimental/observational data 
3.1.1. In vitro seeding of Tau by Sup35NM 
To study the potential of the yeast Sup35 prion for tau protein seeding, we expressed the Sup35NM 
prion domain in E. coli and aggregated it at 4 C into fibrils (Figure S2). Recombinant -5TyrSup35NM 
[40] was used as a non-aggregated seeding control. 
First, we analyzed whether Sup35NM fibrils were capable of directly inducing tau aggregation in 
vitro. The naturally unfolded tau protein does not easily aggregate in vitro without co-factors such as 
heparin. Hence, we incubated either aggregation prone recombinant human 2N4R P301S tau 
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monomers (Figure 1) or 2N4R wild-type tau monomers (Figure 2) in the presence of very low levels 
of heparin (0.02 mg/ml) either unseeded (Figure 1a, Figure 2a), with non-aggregated -5TyrSup35NM 
monomers (Figure 1b, Figure 2b), or with Sup35NM fibril fragments (obtained by sonication of 
Sup35NM fibrils; Figures 1c and 2c).  
Seeding of P301S tau monomers with Sup35NM fibril fragments resulted in the formation of tau 
filaments displaying a distinctly wavy, slightly skewed corkscrew-like pattern (Figure 1c), which was 
only rarely seen in unseeded or -5TyrSup35NM incubated tau samples. As this corkscrew-like 
P301S tau fibril pattern was somewhat reminiscent of the curly tau fibrils previously described upon 
seedings with mutant tau seeds [41], we hypothesize that it might correspond to a specific tau fibril 
strain.  
As expected, unseeded P301S tau monomers aggregated into a wide variety of filaments (Figure 
1a). P301S tau monomers kept with -5TyrSup35NM monomers formed similar filaments as the 
unseeded sample. However, after 3 days of incubation these filaments showed clumpy protein 
decorations that were no longer visible after 16 days (Figure 1b). This suggested a transient 
interaction of the tau monomers with -5TyrSup35NM, which itself also formed fibrils after 16 days 
when kept without tau monomers (Figure S3).  
Strikingly, Sup35NM seeds also provoked rapid aggregation of 2N4R wild-type tau monomers into 
fibrils (Figure 2c). These fibrils again exhibited a characteristic corkscrew-like pattern, with a clear 
preference towards regular wave patterns with a periodicity of around 143 nm (± 12 nm, n = 87) 
(Figure 2c) when observed in negative stain transmission electron microscopy (TEM) images. 
Compared to non-seeded (Figure 2a) or -5TyrSup35NM exposed wild-type tau monomers (Figure 
2b), fibril formation was promoted by Sup35NM seeds, and corkscrew-like fibrils formed already at 
day 3 (Figure 2c). Immuno-gold labelling of the Sup35NM-induced corkscrew-like fibrils confirmed 
that they consist of tau, and not of minute amounts of Sup35NM seeds (Figure S4).  
Next, we created short seeds out of Sup35NM-induced human wild-type 2N4R tau filaments by 
sonication to seed 2N4R wild-type tau monomers. After 3 days we observed rapid formation of tau 
filaments (Figure 3a), which were used for seeding of a next generation of fibrils (Figure 3b). While 
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the aggregation-accelerating effect of the seeds remained, the distinct wave pattern, which was well 
preserved in the first generation of re-seeding, lost its exclusivity during the subsequent seeding 
generation, while morphologies previously seen in heparin-induced samples occurred more often. 
This observed dilution could be attributable to the fact that Sup35NM-induced fibrils occur first due 
to the aggregation-promoting effect of Sup35NM. At later time points it is possible that the interaction 
of tau monomers with heparin is sufficient for fibril formation (as seen for the negative control without 
Sup35NM seeds in Figure 2a). These heparin-induced tau fibrils could then act as templates, and 
therefore the morphology of Sup35NM-induced fibrils becomes less dominant. 
3.1.2 In vivo seeding of Tau by Sup35NM 
Next, we asked the question of whether Sup35NM fibrils have the potential to accentuate tau 
pathology in vivo. To this end, we inoculated pre-aggregated Sup35NM fibrils into the hippocampus 
of P301S mice. These mice express the human full-length 0N4R tau isoform with the P301S tau 
mutation present in hereditary forms of frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17TAU) [42-44]. P301S tau mice develop slowly progressive intraneuronal 
tau inclusions, which become accentuated upon the inoculation of β-sheet structured tau seeds [44]. 
Sup35NM, -5TyrSup35NM and brain homogenate of non-transgenic C57BL/6 mice (termed B6-bh) 
were used as seeding material for comparison. We inoculated 2.5 l of Sup35NM pre-formed fibrils, 
or -5TyrSup35NM, or B6-bh solutions into the right hippocampus of 3-months-old P301S tau 
transgenic mice. At three months post-inoculation, a strong accentuation of tau pathology was noted 
at the hippocampal inoculation site and along the injection canal (Figure 4a-d, Figure 5). The 
accentuation of tau pathology in the CA3 field upon Sup35NM injection was consistent when 
comparing these mice to B6-bh-injected P301S controls (Figure 4a, c, Table S1). As Sup35NM only 
remains non-aggregated when high amounts of detergents are present, i.e. conditions incompatible 
with in vivo experiments, we used the less aggregating -5TyrSup35NM mutant as negative control. 
Indeed, only a mild, non-significant increase in tau pathology was noted in -5TyrSup35NM seeded 
mice when compared to B6-bh inoculated mice (Figure 4a, c, Table S1). This observation paralleled 
our in vitro findings of a limited short-term interaction between -5TyrSup35NM and P301S tau that 
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did not obviously change tau fibril structure. Moreover, our experiment also confirmed the strong 
aggregation propensity of Sup35NM, which partly persists even with the -5Tyr deletion [45].  
Quantitative estimates confirmed an increase in hippocampal tau pathology in the CA3 sector of the 
Sup35NM inoculated ipsilateral hippocampus when compared to the contralateral (non-seeded) side 
(Figure 4b, d, Table S2). Similar to the seeding effects of brain extracts from tauopathy patients in 
P301S host mice [46], we noted the induction of Gallyas-Braak positive grains in the dorsal fornix in 
a subset of Sup35NM seeded mice, mostly in close proximity to the inoculation canal (Figure 5a, b). 
These findings are compatible with a robust in vivo seeding effect of Sup35NM and mild, non-
significant residual seeding effects of the less aggregation prone -5TyrSup35NM mutant. 
3.1.1 Future Experiments and Validation Studies 
Our proof of concept experiments demonstrating cross-species cross-seeding of tau protein by a 
yeast prion should be validated in other model systems, studying the cross-seeding potential of other 
non-mammalian prions with tau and other neurodegenerative prion-like proteins. In the context of 
AD, cross-seeding of Sup35 and amyloid-β should be studied. Like tau, amyloid-β is susceptible to 
cross-seeding, e.g. by IAPP [47, 48] and α-synuclein [17]. 
Further studies should characterize the interaction of various bacterial and plant prions [20-24] with 
tau and amyloid-β. As a more complex task, the search for yet unidentified non-mammalian prion 
proteins, which may act as exogenous seeds or which are generated by the human microbiome, will 
be instrumental. Recently developed algorithms to identify proteins with prion-like properties may 
support the discovery of such microbiome-associated prions [20, 49, 50]. To make the case for a 
truly pathogenetic role of non-mammalian prions in the pathogenesis of AD, clinical studies will 
eventually be required to investigate the prevalence of such microbiological or exogenous prions 
e.g. in the nasal cavity or the olfactory bulb of AD patients. Identification of specific non-mammalian 
prion seeds could ultimately result in novel preventive, diagnostic and therapeutic approaches to 





4.  Major challenges for the hypothesis 
Here, we provide first evidence for tau seeding by an archaic yeast prion. While our observations 
serve well as a proof of principle, it remains unclear whether yeast prions play a relevant role in the 
pathogenesis of AD or other tauopathies. To this end, analyzing e.g. the presence of microbiome-
associated prions in AD patients will be instrumental (see Future Experiments and Validation 
Studies).  
The observed tau seeding effect of Sup35NM (and our hypothesis) suggest that certain (archaic) 
prions might retain a broad seeding capacity. To verify this assumption, the interaction of various 
prions and prion-like proteins from different species will have to be studied. This may part prions into 
a hierarchic cross-seeding system, separating highly cross-seeding competent prions from others, 
which might be more “seedable”. Some recent data would well support such a hierarchic cross-
seeding system: e.g., IAPP aggregates were able to seed -synuclein monomers, but not vice versa 
[51]; E. coli-derived Curli protein aggregates seeded -synuclein, while they were unable to seed 
tau monomers [52]. 
In light of the growing evidence for disease-specific fibril strains in tauopathies, our hypothesis will 
also have to face the challenge of whether non-mammalian prions will be able to induce tau strains 
similar to those detected in tauopathy patients [3-5]. Future cryo-EM studies may provide insights 
into the strain structures of cross-seeded tau aggregates.  
Next, we discuss how our hypothesis addresses the critical questions confronting all major theories 
of Alzheimer’s dementia, as suggested by Khachaturian et al. [53]. 
A non-mammalian prion-induced templating of tau protein in AD would well explain the characteristic 
association of the disease with age. Templated seedings of neurodegenerative prion-like proteins 
are typically associated with very long incubation periods, even when seed and seeded protein share 
their primary structure. Incubation times of up to three decades were noted in patients with iatrogenic 
PrPSc infections or amyloid- transmissions by contaminated growth hormone or gonadotropin [54, 
55], reaching even five decades in people infected with Kuru via cannibalism [56]. In this context, 
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exposure to microbiotic or exogenous non-mammalian prions early in life would be followed by a 
long incubation period in sporadic AD. Thus, our putative theory might explain the relationship 
between the biology of aging and the biology of AD pathology. 
Genome-wide association studies identified a set of genetic variants in AD which were mapping to 
distinct biological pathways, including protein misfolding, protein ubiquitination as well as 
endocytosis [57, 58]. These latter pathways would be in good agreement with our hypothesis of a 
prion-induced provocation of tau misfolding. All three biological pathways are directly linked to prion-
like protein aggregation and would be expected to be involved in heterotypic tau seeding.  
In the context of AD risk factors, type 2 diabetes has increasingly been studied [59-61]. Recently, 
heterotypic seeding of tau by a diabetes-associated prion-like protein has been reported. Diabetes 
associated IAPP was shown to cross-seed tau as well as α-synuclein [19, 51]. This provides an 
example of structure-based heterotypic, yet still mammalian protein based cross-seeding of amyloid 
aggregates in the context of AD and relates well to our proposed induction of tau aggregation by 
non-mammalian -structured templates. In this context, our hypothesis may also explain the 
relationships between known risk or protective factors and the neurobiological mechanisms by which 
they modify risk.  
Our hypothesis assumes, amongst others, a primarily transnasal route of tau cross-seeding by either 
exogenous non-mammalian prions or prions generated by the microbiome of the nasal cavity. 
Heterotypic non-mammalian prions may enter the cranium from the nasopharyngeal cavity similar to 
viruses [62, 63]. From the olfactory bulb they may follow the olfactory nerve, which projects to the 
entorhinal cortex, the amygdala and the hippocampus [64, 65]. Heterotypic cross-seeding of tau may 
occur in the first neurons of the olfactory network, as early tau pathology has been described in the 
olfactory system [66, 67]. Once tau aggregation is initiated, it can subsequently spread by its own 
via trans-neuronal spreading [6, 68], resulting in the characteristic Braak’s stages of tau pathology 
progression in AD [69]. In line with this, olfactory dysfunction occurs as an early symptom in many 
patients with mild cognitive impairment (MCI) or AD [70-73]. The proposed pattern of spreading of 
tau aggregation from the olfactory bulb towards the limbic system, with subsequent involvement of 
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cortical structures also mirrors the clinical course and progression of tau pathology in AD [74, 75]. 
As our hypothesis addresses the very first step of tau aggregation in AD, it is in full compliance with 
all present knowledge on the course of tau pathology and associated neuronal dysfunction in AD. It 
therefore not only explains how and when the clinical manifestations relate to pathophysiology, but 
also provides a plausible explanation for the anatomical specificity of early lesions associated with 
AD. 
Our hypothesis also accounts well for the mixed pathology noted in AD and other tauopathies, where 
different neurodegenerative prion-like proteins co-occur. Tau can be seeded by various other 
neurodegenerative prion-like proteins, including α-synuclein [14, 15, 76] and amyloid-β [9, 18],  as 
well as by non-neurodegenerative prion-like proteins like IAPP [19]. Furthermore, tau has the ability 
to form various tau strains which acquire unique conformational features and quaternary structures 
[3, 4, 77-79]. The transmission of distinct tau strains is specific to unique pathological conformations 
[80]. Therefore, different non-mammalian prion seeds could provoke the formation of different tau 
strains, resulting in different disease manifestations and clinical heterogeneity.   
Our theory is also in line with the importance of tau as a biomarker, both in the cerebrospinal fluid 
as well as in AD imaging. With our hypothesis currently still at a proof of concept stage, detailed 
considerations on future biomarkers targeting non-mammalian prions for prognosis and risk 
stratification in AD would be premature. In the case of identification, non-mammalian prions related 









4. Linkage to other major theories  
Here, we propose that seeding of tau and/or amyloid- by non-mammalian prion proteins might 
constitute a key trigger event in the cascade of AD. The amyloid cascade hypothesis or amyloid- 
hypothesis, established in the 1990ies, postulated a crucial role of amyloid- aggregation for the 
pathogenesis of AD, considering tau as a downstream effector [81, 82]. Our hypothesis is compatible 
with this idea of tau aggregation as a downstream event in the cascade of AD, but modifies the 
amyloid hypothesis towards a model where cross-seeding of tau and amyloid-β can also be provoked 
by heterotypic non-mammalian prions.  
Our present hypothesis is related to the rapidly growing number of discoveries of non-mammalian 
prions in fungi, bacteria, plants and even viruses [7, 20-25]. This recent diversification of the prion 
family was paralleled by the notion that several prions share similar functions. As an example, tau 
and Sup35 are both involved in phase separation [34, 35], and a prebiotic regulatory function of 
amyloids has been suggested [83]. This opens up the perspective that prions may interact across 
species, even though species barriers have previously been established for many prion disorders 
[84]. Our hypothesis thus extends the prion hypothesis to prion cross-infections in the context of 
neurodegenerative disorders. 
An infectious pathway has been proposed earlier for AD, outlining a potential route of infection 
reaching the limbic system from the nasal cavity via olfactory bulb and nerve [66, 85]. The viral 
infectious hypothesis builds on the predominant limbic involvement in cerebral HSV infections and 
the early affection of the limbic system in AD [86], and the occurrence of neurofibrillary tangles as 
possible late sequelae of early infections with measles [87]. However, in most infection related 
models, the direct mechanistic link from the proposed viral or bacterial infection to the characteristic 
protein misfolding of tau or amyloid-β remains yet unidentified [88]. Our hypothesis provides a 
structural basis for a prion-induced misfolding of tau or amyloid-β into prion-like β-structured fibrils 
upon a protein-only infection by non-mammalian prion particles.  
In analogy to our proposed model of a transnasal infectious pathway in AD, an initial induction of -
synuclein aggregation by a yet unknown agent in the gut has been proposed by Braak and coworkers 
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for Parkinson’s disease [89]. Recently, a gut bacterial prion was found to cross-seed -synuclein 
[52]. This supports our present hypothesis of a non-mammalian prion-mediated induction of tau and 
amyloid-β aggregation in AD and other tauopathies.   
As AD and other tauopathies present with clinical and pathological heterogeneity [90, 91], even within 
familial forms of AD [92], we are well aware that various pathomechanisms may co-occur and 
interplay in these disorders. Amongst others, the induction of tau aggregation is known to be 
facilitated by other structural changes, e.g. tau mutations, which render the soluble tau protein more 
aggregation prone [93, 94]. Tau cleavage may furthermore generate tau fragments which can seed 
full-length tau into toxic aggregates [95]. Our present hypothesis shall therefore not be 
misunderstood as an exclusive proposition, but rather as an extension to the spectrum of possible 
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Figure 1. Sup35NM seeds P301S mutant tau aggregation in vitro.  
a-c, TEM images of negatively stained preparations of human 2N4R P301S mutant tau monomer 
aggregates, formed under low heparin conditions (a), and after addition of -5TyrSup35NM monomers 
(b), or Sup35NM seeds (c), at days 0, 3, and 16. Note the occurrence of corkscrew-like shaped tau 
fibrils at day 3 and 16 upon seeding with Sup35NM fibrils (arrows, c). Scale bar for all images: 500 







Figure 2. Sup35NM seeds wild-type tau aggregation in vitro.  
a-c, TEM images of negatively stained preparations of human 2N4R wild-type tau monomer 
aggregation under low heparin conditions (a), and after addition of -5TyrSup35NM monomers (b), or 
Sup35NM seeds (c), at days 0, 3, and 16. Note the occurrence of corkscrew-like shaped tau fibrils 
at day 3 and 16 upon seeding with Sup35NM fibrils (arrows, c). Scale bar for all images: 500 nm, for 








Figure 3. Re-seedings of tau monomers by Sup35NM-induced wild-type tau filaments.  
a, b, TEM images of negatively stained preparations of human 2N4R wild-type tau monomer 
aggregation under low heparin conditions at time points day 0 and day 3, using corkscrew-like 2N4R 
wild-type tau filaments (termed Generation 0 seeds), which were previously induced by Sup35NM 
seeds. This resulted in a next generation (Generation 1 (G1)) of corkscrew-like filaments (arrow, a). 
Re-seeding with G1 filaments again induced corkscrew-like tau aggregates in generation 2 (G2) 






Figure 4. Sup35NM seeds tau aggregation in P301S tau transgenic mice.  
a-d, increase in AT8 immunohistochemistry (AT8) and Gallyas-Braak staining (GALL) positive 
neurons in the unilateral CA3 field after intrahippocampal Sup35NM fibril inoculation in P301S tau 
transgenic mice.  AT8 and Gallyas-Braak positive neurons comparing P301S tau mice inoculated 
with C57BL/6 mouse brain homogenates (B6-bh), -5TyrSup35NM solution, and Sup35NM fibrils (a, 
c; one-way ANOVA, followed by Tukey’s test), and corresponding histology (Bregma level -2.6mm). 
Comparison of the non-injected (contralateral) to the injected (ipsilateral) side (b, d; paired T-tests), 
and representative histological findings (Bregma level -2.4mm). *p<0.05, **p<0.01, n.s. = non-
significant; indicated is the mean positive neuron number in CA3 per section  standard deviation. 





 Figure 5. Sup35NM induces focal tau pathology 
Focal tau pathology induced around the hippocampal inoculation canal and the ipsilateral dorsal 
fornix upon Sup35NM inoculation. a, b, Gallyas-Braak stains. Note the characteristic focal grain-like 
tau aggregates in proximity of the hippocampal injection canal upon Sup35NM inoculation (a, arrows 
indicate tau pathology along the inoculation canal). Granular tau pathology develops in the ipsilateral 
dorsal fornix of a SUP35NM-seeded P301S mouse (b, right; arrow), but is absent in the contralateral 



















2.1.1 Supplementary data - Figures and Tables 
 




 Figure S1. Schematic of our proof of concept experiments. 
Tau aggregation is a defining characteristic of a number of human neurodegenerative diseases, 
including Alzheimer’s disease. The cause of tau aggregation in neurodegenerative disorders has yet 
remained unclear. We hypothesize that seeding of tau protein by non-mammalian prions my play a 
role in the pathogenesis of tauopathies. 
Sup35 is a prion protein which forms heritable aggregates in yeast. Sup35 aggregates show similar 
β-sheet structures as tau fibrils. As a proof of concept, we here study whether the Sup35NM prion 
domain can promote the aggregation of human tau. In vitro, Sup35NM fibrils provoke accelerated 
tau misfolding, resulting in increased formation of corkscrew-shaped tau fibrils. In vivo, we find that 
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inoculation of tau transgenic mice with fibrils of the Sup35NM prion domain accentuates tau 
pathology in the hippocampus of recipient animals. 
This demonstrates that an archaic non-human prion can seed the aggregation of a human prion-like 
protein in a heterotypic manner.  
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Figure S2  
  
Figure S2. -5TyrSup35NM and Sup35NM preparations 







Figure S3. In vitro seeding controls.  
a, b, TEM images of negatively stained -5TyrSup35NM monomer (a), or Sup35NM seed (b) 
aggregation under low heparin conditions at days 0, 3, and 16 in the absence of tau monomers. 






Figure S4. Immuno-gold labelling of Sup35NM-induced P301S mutant tau filaments and Sup35NM-
induced wild-type tau filaments 
Immuno-gold labelling with the HT7 antibody is negative for Sup35NM seeds alone, but labels the 
corkscrew-like fibrils obtained upon seeding of P301S tau monomers or wild-type tau monomers with 
Sup35NM seeds, confirming that these filaments consist of tau. Scale bar for all images: 200 nm, for 






2. Supplementary Tables 
Table S1 
Quantitative data of AT8 immunohistochemistry and Gallyas-Braak silver stain positive neurons 
comparing tau pathology between B6-bh injected mice, -5TyrSup35NM inoculated mice, and 
Sup35NM seeded mice (mean  SD). 
 B6-bh -5TyrSup35NM Sup35NM 
ANOVA, p-Values  






13.95  12.14 
 
(n=10) 
29.18  5.43 
 
(n=8) 
35.55  15.70 
 
(n=7) 
ANOVA: p= 0.004 
p= 0.511 (B6-bh versus -5TyrSup35NM) 
p= 0.047 (-5TyrSup35NM versus Sup35NM) 






11.03  9.75 
 
(n=10) 
18.74  9.10 
 
(n=9) 
28.18  13.92 
 
(n=9) 
ANOVA: p= 0.009 
p= 0.301 (B6-bh versus -5TyrSup35NM) 
p= 0.188 (-5TyrSup35NM versus Sup35NM) 







Quantitative data of AT8 immunohistochemistry and Gallyas-Braak silver stain positive neurons 
comparing contralateral and ipsilateral tau pathology of Sup35NM seeded mice. 
 
Mean contralateral  
(n per group) 
Mean ipsilateral 




Mean AT8 positive 
neurons in CA3,   
 SD 
22.07  8.06 
(n=7) 




positive neurons in CA3,   
 SD 
14.54  7.15 
(n=9) 



























Average age of seeded mice at perfusion per group.  
 B6-bh -5TyrSup35NM Sup35NM 
Months 
6.61  0.56 
 
(n=10) 
6.19  0.40 
 
(n=9) 
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Tau is a microtubule stabilizing protein that forms abnormal aggregates in many neurodegenerative disorders, 
including Alzheimer’s disease. We have previously shown that co-expression of fragmented and full-length 
tau in P301SxTAU62on tau transgenic mice results in the formation of oligomeric tau species and causes severe 
paralysis. This paralysis is fully reversible once expression of the tau fragment is halted, even though P301S 
tau expression is maintained. Whereas various strategies to target tau aggregation have been developed, little 
is known about the long-term consequences of reverted tau toxicity.  
Therefore, we studied the long-term motor fitness of recovered, formerly paralyzed P301SxTAU62on-off mice. 
To further assess the seeding competence of oligomeric toxic tau species, we also inoculated ALZ17 mice with 
brainstem homogenates from paralyzed P301SxTAU62on mice.  
Counterintuitively, after recovery from paralysis due to oligomeric tau species expression, aging 
P301SxTAU62on-off mice did not develop more motor impairment or tau pathology when compared to 
heterozygous P301S tau transgenic littermates. Thus, toxic tau species causing extensive neuronal dysfunction 
can be cleared without inducing seeding effects. Moreover, these toxic tau species also lack long-term tau 
seeding effects upon intrahippocampal inoculation into ALZ17 mice.  
In conclusion, tau species can be neurotoxic in the absence of seeding-competent tau aggregates, and mice can 
clear these tau forms permanently without tau seeding or spreading effects. These observations suggest that 
early targeting of non-fibrillar tau species may represent a therapeutically effective intervention in tauopathies. 
On the other hand, the absent seeding competence of early toxic tau species also warrants caution when using 
seeding-based tests for preclinical tauopathy diagnostics.  
 
 







AD: Alzheimer’s disease 
NFT: Neurofibrillary tangles 
H&E: Hematoxylin and eosin 
HRP: Horseradish peroxidase 
ANOVA: Analysis of variance 
AgD: Argyrophilic grain disease 
PSP: Progressive supranuclear palsy 















Tau is a soluble protein acting as a microtubule stabilizer in neuronal cells. Under pathological conditions it 
becomes hyperphosphorylated and eventually forms intracellular aggregates. Tau aggregates are a hallmark of 
Alzheimer’s disease (AD) and other neurodegenerative disorders, including forms of frontotemporal dementia 
(Spillantini and Goedert, 2013; Spires-Jones and Hyman, 2014). The mechanisms underlying pathological tau 
aggregation remain only partly understood. Tau is thought to aggregate through the formation of oligomeric 
species and subsequent aggregation into fibrils, culminating in the formation of tangles. Tau aggregation can 
spread towards anatomically connected regions in a prion-like manner (Clavaguera et al., 2009; Goedert et al., 
2017).  
We have recently shown that tau toxicity can be mediated by oligomeric tau species (Ozcelik et al., 2016). Co-
expression of full-length P301S mutant tau with a 3R tau151-421 fragment (tau151-421) in 3-weeks-old 
P301SxTAU62on transgenic mice leads to the formation of soluble high molecular weight tau oligomers. In the 
P301SxTAU62on mouse model, high molecular weight tau oligomers are sufficient to cause extensive nerve 
cell dysfunction and severe motor palsy, both of which occur in the absence of insoluble tau aggregates or 
neurofibrillary tangles (NFTs) (Ozcelik et al., 2016). Strikingly, once the doxycycline-inducible expression of 
tau151-421 is switched off in these mice, their severe phenotype reverses within 3 weeks, and animals regain 
their motor competence, even though heterozygous P301S mutant tau expression is maintained (Ozcelik et al., 
2016). This phenotype reversibility renders P301SxTAU62on-off mice suitable for investigating potential long-
term consequences of reverted tau toxicity. The relevance of oligomeric tau toxicity is being increasingly 
recognized, and recent studies have shown that it can also be pharmacologically attenuated (Bittar et al., 2019; 
Lo et al., 2019; Abskharon et al., 2020; Lo Cascio et al., 2020; Puangmalai et al., 2020). Hypothesized to 
depend on oligomer conformation, tau oligomeric toxicity can also be aggravated by biological interactions 
with chaperones (Oroz et al., 2018), RNA-binding proteins (Jiang et al., 2019), and nuclear complexes 
(Eftekharzadeh et al., 2018). Due to their interaction with cellular components and their importance in tau 
propagation, tau oligomers have been considered crucial for tau-mediated neurodegeneration. 
Long-term effects after recovery from oligomeric, non-fibrillar tau toxicity have not yet been assessed. Only 
few studies, using inducible tau mouse models, have analyzed the reversibility of tau tangle pathology 
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(Santacruz et al., 2005; Polydoro et al., 2013). Here, we study the late effects of reverted tau stress in aged 
P301SxTAU62on-off mice. Seeding and spreading of tau pathology have been widely studied in human 
tauopathies as well as in tau transgenic mouse models (Maeda et al., 2007; Clavaguera et al., 2009; Sanders et 
al., 2014; Mudher et al., 2017). Based on this accumulated evidence, we hypothesized that the tau oligomers 
abundantly present in young paralyzed P301SxTAU62on mice might act as seed for tau accumulation, as P301S 
full-length tau expression is maintained, while doxycycline-driven tau151-421 expression is switched off. To 
our surprise, P301SxTAU62on-off mice that had recovered from neurotoxic stress and motor palsy did not 
develop worse motor function nor more pronounced tau pathology during aging when compared to their P301S 
tau heterozygous littermates. This demonstrates that P301SxTAU62on-off mice clear their toxic tau aggregates 
without seeding NFT formation, and hence do not show pronounced motor decline upon aging. 
To study whether the toxic tau species causing palsy in young P301SxTAU62on mice also lack classical seeding 
competence, we next stereotactically inoculated brainstem homogenates of paralyzed P301SxTAU62on into 
ALZ17 human wild-type tau transgenic mice. In contrast to ALZ17 mice seeded with P301S brainstem 
homogenates containing fibrillary tau species (Clavaguera et al., 2009), ALZ17 mice inoculated with 
P301SxTAU62on homogenate did not develop fibrillar tau pathology, arguing against a seeding competence of 
the early toxic tau forms in P301SxTAU62on mice. 
Lacking seeding competence of non-fibrillar toxic tau species as well as absent long-term sequelae after halting 
their expression warrants the exploration of early therapeutic interventions targeting pre-fibrillar tau species. 








Transgenic homozygous mice expressing human ALZ17 mutant tau (ALZ17 mice) (Probst et al., 2000), 
transgenic homozygous mice expressing human P301S mutant tau (P301S mice) (Allen et al., 2002), 
transgenic heterozygous mice expressing human Δtau151-421 (TAU62 mice) (Ozcelik et al., 2016), and non-
transgenic C57BL/6J (BL6 mice) control mice were used. P301S mice and TAU62 mice were interbred to 
obtain double transgenic P301SxTAU62 mice (Ozcelik et al., 2016). All animal experiments were performed 
in compliance with protocols approved by the Committee for Animal Care and Animal Use of the Canton of 
Basel (Licenses Nr. BS 2364 and 2471). 
Behavioral tests 
Motor behavior, including gait ataxia, tremor, and hindlimb reflexes was assessed. Quantitative motor testing 
was performed by the grid test in which mice were placed on a vertical mesh grid and the latency to fall off 
the grid was recorded for 3 min. Motor coordination and balance were assessed using the Panlab Harvard 
Rotarod (Harvard Apparatus, Holliston, USA). The rotarod starts at a speed of 4 rpm and accelerates by 1 rpm 
every 3 sec. In both, grid test and rotarod assay, mice were tested for 3 consecutive days with 3 trials per day, 
with minimum rest intervals of 5 min, and the mean latency to fall was documented. Results were obtained by 
averaging the daily means of 3 consecutive days. 
Stereotactic surgery 
For surgery, 3-months-old ALZ17 mice were anesthetized with a mixture of ketamine (10 mg/kg) and xylazine 
(20 mg/kg) and placed on a heating pad to maintain body temperature. Mice were stereotactically injected into 
the right hippocampus (A/P, −2.5 mm from bregma; L, − 2.0 mm; D/V, −1.8 mm) using a Hamilton syringe. 
Brainstem homogenates of 6-months-old paralyzed homozygous P301S mice and 3-weeks-old paralyzed 
P301SxTAU62on mice were prepared for inoculation in ALZ17 mice. Brainstems were weighted and diluted 
1:10 in PBS for seeding. After dilution, samples were homogenized using an Ultraturrax T8 (IKA 
Labortechnik, Staufen im Breisgau, Germany) and sonicated briefly (Bandelin SONOPULS, Bandelin, Berlin, 
Germany; 90% power, 10% cycle, 10 sec pulses). Homogenates were then centrifuged at 4000 g for 20 minutes 
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at 4 °C, and aliquots of the supernatant were stored at -70 °C for later usage. During inoculation, each mouse 
received 5 μl of brainstem homogenate at a speed of 1.25 μl/min. Following injection, the needle was kept in 
place for additional 3 minutes before withdrawal. The surgical area was cleaned with sterile saline and the 
incision sutured. Mice were monitored until recovery from anaesthesia, post-interventional analgesia was 
administered, and animals were checked regularly following surgery. After 20 months of incubation, the 
seeded mice were sacrificed. 
Immunohistochemistry 
Mice were deeply anesthetized with pentobarbital and transcardially perfused with 20 ml cold PBS, followed 
by 20 ml 4% paraformaldehyde in PBS. The brains were dissected and post-fixed overnight. Following paraffin 
embedding, 4 μm coronal sections were cut from the brains of seeded mice, whereas 4 μm sagittal sections 
were prepared from the brains of mice used for the behavioral tests. Sections were silver-impregnated 
following the method of Gallyas-Braak to visualize filamentous tau pathology. Hematoxylin and eosin staining 
(H&E) was performed for morphological analysis. For immunohistochemistry, the following anti-tau 
antibodies were used: AT8 (1:1000, Pierce Biotechnology, Waltham, USA), AT100 (1:1000, Pierce 
Biotechnology, Waltham, USA), TauC3 (1:1000, Santa Cruz Biotechnology, Santa Cruz, USA). Secondary 
antibodies were from Vector Laboratories, Burlingame, USA (Vectastain ABC kit). 10X, 20X and 40X 
magnified pictures of the stained slides were taken with an Olympus BX43 Upright Microscope (Life Sciences 
Solutions, Chicago, USA). 
Western blots 
For the western blots comparing total and soluble tau in 16-months-old P301S heterozygous (P301Shet) and 
P301SxTAU62on-off mice, brains were homogenized in cold extraction buffer 20 % (w/v) (25 mM Tris-HCl pH 
7.4, 150 mM NaCl, 1mM EDTA, 1mM EGTA, 5 mM NaPyrophosphate, 10 mM B Glycerophosphate, 30 mM 
NaFluoride, 10 mM NaVanadate, with addition of 100 ul/10 ml PMSF of 0.1 M just before use, and 1 Pierce 
protease and phosphatase inhibitor mini tablet, EDTA-free, Pierce Biotechnology, Waltham, USA) using a 
Polytron Homogenizer (Thomas Scientific). An aliquot of the resulting homogenate was collected as total tau. 
Subsequently, samples were centrifuged at 80000 g for 15 min using an ultracentrifuge (Beckman Coulter, 
Brea, USA; OptimaTM L-70K Ultracentrifuge), and an aliquot of the supernatant was collected as soluble tau. 
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For the western blot comparing total tau in 3-months-old mice, one half of the mouse brain was dissected into 
forebrain and brainstem, and frozen in liquid nitrogen or on dry ice. Brainstems were weighted and diluted 
1:10 in TBS-Complete. Subsequently, samples were homogenized using an Ultraturrax T8 (IKA Labortechnik, 
Staufen im Breisgau, Germany) and briefly sonicated (Bandelin SONOPULS, Bandelin, Berlin, Germany; 
90% power, 10% cycle, 10 sec pulses). Homogenates were then centrifuged at 4000 g for 20 minutes at 4 °C, 
and aliquots of the supernatant stored at -70 °C for later usage. Western blots were then performed under non-
reducing conditions using appropriate amounts of protein, 4X NuPAGE LDS sample buffer, and deionized 
water. 10X NuPAGE reducing agent was used to obtain reducing conditions. Following appropriate 
preparation, samples were loaded onto a 7% NuPAGE® Tris-acetate gel. After the removal of gels from the 
cassette and activation of PVDF membrane (Amersham Biosciences, Amersham, UK) samples were 
transferred on the PVDF membrane using the XCell IITM Blot Module. Unspecific binding epitopes were 
blocked with 5% non-fat milk in PBS-Tween, followed by incubation with primary antibody over night at 4 
°C on a shaker. After washing with PBS-Tween, the membrane was incubated with horseradish peroxidase 
(HRP)-conjugated anti-mouse or -rabbit secondary antibody at room temperature. Then, the membrane was 
washed again in PBS-Tween and detected by electrochemiluminescence (ECL) (GE Healthcare, Little 
Chalfont, UK). The anti-tau antibody used for the western blots was HT7 (1:1000, Pierce Biotechnology, 
Waltham, USA). 
Dot blots 
For dot blots, serum of 3-months-old P301Shet and P301SxTAU62on-off mice was separated from the clot by 
centrifuging the samples at 1000 rpm for 15 minutes at 4 °C, with the remaining supernatant aliquoted and 
stored at -20 °C, for later usage. Then, a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, USA) 
was divided in a grid to allow later incubations with 3-months-old P301Shet and P301SxTAU62on-off sera and 
HT7 antibody as positive control at 1:1000 dilutions. 0.2 mg/ml of 2N4R wild-type tau monomers were applied 
on a 4x3 grid. Next, unspecific binding epitopes were blocked with 5% BSA in PBS-Tween, followed by a 30-
minutes-long incubation at room temperature with previously extracted sera from the mice and HT7 antibody 
as positive control. After washing with PBS-Tween, the membrane was incubated with HRP-conjugated anti-
mouse secondary antibody at room temperature, washed again in PBS-Tween, and detected by ECL (GE 




To evaluate behavioral test results statistically, one-way analysis of variance (ANOVA) followed by post-hoc 
Student’s t-tests and Bonferroni correction for multiple comparisons were applied. P-values < 0.05 were 
considered significant. To estimate soluble tau and total tau expression from western blots of 3-months-old 
and 16-months-old mice, the protein bands were normalized to GAPDH protein standard, and quantified using 
ImageJ software; generated mean ratio values were compared by Student’s t-test. To determine the effect of 
early neurotoxic stress in aged mice, AT8 and Gallyas-positive neurons were semi-quantitatively assessed in 
brainstem regions. Three sections per animal were analyzed. The total area analyzed per animal was 
comparable between animals (AT8: P-value = 0,34, and Gallyas: P-value = 0,91). The average count/area 
ratios were obtained. P-values calculated by Student’s t-tests were interpreted exploratory and not adjusted for 
multiple comparisons; P-values < 0.05 were considered significant. Box plots for figures 2 to 5 were generated 
with R software. The lower and upper hinges correspond to the first and third quartiles (25th and 75th 
percentiles). The upper whisker extends from the hinge to the largest value no further than 1.5 times IQR from 
the hinge (where IQR is the inter-quartile range, or distance between the first and third quartiles). The lower 
whisker extends from the hinge to the smallest value at most 1.5 times IQR of the hinge. Data beyond the end 
of the whiskers are called "outlying" points and are plotted individually. 
Availability of data and materials 






Co-expression of tau fragment and full-length tau induces severe reversible neurotoxicity in 
P301SxTAU62on mice despite the absence of tau fibrils 
P301SxTAU62on transgenic mice co-expressing human Δtau151-421 with full-length P301S mutant tau were 
obtained by interbreeding P301S tau transgenic mice with TAU62 transgenic mice, where Δtau151-421 
expression is regulated by a doxycycline-responsive promoter element (Ozcelik et al., 2016). 3-weeks-old 
heterozygous P301S transgenic littermates (P301Shet) did not exhibit signs of motor dysfunction, as also 
illustrated by their normal tail suspension test (Fig. 1A). In contrast, P301SxTAU62on mice of the same age 
showed a severe hindlimb palsy, only being able to move by the use of their forelimbs (Fig. 1B). Upon halting 
doxycycline administration to stop Δtau151-421 expression, this phenotype was fully reversible within three 
weeks, even though P301S tau expression continued (Fig. 1C).  
Histological examination did not reveal any tau pathology in young P301Shet mice (Fig. 1A). In contrast, 
extensive AT8-positive pre-tangle stage tau pathology was found in paralyzed, 3-weeks-old P301SxTAU62on 
mice (Fig. 1B). Remarkably, three weeks after Δtau151-421 expression had been stopped, AT8-positive tau 
pathology was no longer detectable, and by the age of six weeks, P301SxTAU62on-off mice had regained normal 
walking capability (Fig. 1C). Gallyas-Braak silver stain positive tau pathology was absent in 3-weeks-old 
P301Shet mice (Fig. 1A), their paralyzed P301SxTAU62on littermates (Fig. 1B), as well as in recovered 
P301SxTAU62on-off mice (Fig. 1C, for high magnification pictures see Supplementary Fig. 1). These 
observations confirm that the severe, but reversible motor palsy in P301SxTAU62on-off mice is mediated by 
non-fibrillar, Gallyas-Braak silver stain-negative tau species (Ozcelik et al., 2016).  A graphical representation 
of these findings is given in Supplementary Fig. 2. 
 
Absence of excessive motor impairment in aged P301SXTAU62on-off mice after recovery from early 
severe neurotoxicity 
To study the long-term effects of the severe non-fibrillar tau stress in P301SxTAU62on mice, we followed their 
motor capabilities after their initial recovery. As only Δtau151-421 expression is under the control of a 
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doxycycline-responsive promoter element, recovered P301SxTAU62on-off mice maintain expression of P301S 
mutant full-length tau.  
We compared formerly paralyzed, recovered and aged P301SxTAU62on-off mice to their P301Shet littermates 
and to non-transgenic BL6 mice by tail suspension, rotarod, and grid tests at the age of 16 months. P301Shet 
littermates showed signs of hindlimb clasping, while recovered P301SxTAU62on-off mice were still able to 
spread their hindlimbs, as were non-transgenic BL6 mice (Fig. 2A).  
As expected, at 16 months of age, motor balance (rotarod) was significantly reduced in both tau expressing 
mouse models, compared to non-transgenic BL6 mice. Somewhat surprisingly, however, we did not detect a 
worse motor performance of P301SxTAU62on-off mice in comparison to their P301Shet littermates. In contrast, 
formerly paralyzed P301SxTAU62on-off mice performed even slightly better in the rotarod test when compared 
to P301Shet littermates, although this did not reach statistical significance (Fig. 2B). Similar observations were 
made for the grid test, revealing a significantly reduced motor strength in P301Shet transgenic mice in 
comparison to non-transgenic BL6 mice. Again, at the age of 16 months, P301SxTAU62on-off mice showed a 
slightly better grid test performance than their P301Shet littermates, although again without statistical 
significance (Fig. 2C, see Supplementary Table 1 for complete values). Thus, P301SxTAU62on-off mice 
recovered from early neurotoxic tau stress and did not show increased motor impairment with aging when 
compared to P301Shet littermates. These findings are graphically summarized in Supplementary Fig. 2. 
 
Absence of excessive tau pathology in aged P301SxTAU62on-off mice after recovery from severe 
neurotoxicity 
We next aimed at studying whether the absence of a pronounced motor phenotype in P301SxTAU62on-off mice 
would also be mirrored by the extent of tau pathology upon aging. To this end, we comparatively analyzed 
brains of 16-months-old P301SxTAU62on-off and P301Shet mice by histology. In all mice, tau pathology was 
most extensive in the brainstem. AT8 immunohistochemistry revealed extensive tau hyperphosphorylation in 
P301Shet mice whereas significantly less tau hyperphosphorylation was present in P301SxTAU62on-off animals 
(Fig. 3A, B, for high magnification pictures see Supplementary Fig. 3). Additional immunohistochemistry with 
the AT100 antibody revealed similar results for 16-months-old mice, confirming the significantly more 
 
 73 
abundant hyperphosphorylation in the heterozygous mice which did not experience the early neurotoxic stress 
as the recovered mice did (see Supplementary Fig. 4). 
Gallyas-Braak silver staining revealed widespread, robust tau tangle formation in the brainstem of P301Shet 
mice, whereas formerly paralyzed P301SxTAU62on-off mice remained almost devoid of fibrillar tau pathology 
(Fig. 3C, D, for high magnification pictures see Supplementary Fig. 3). Semiquantitative assessment confirmed 
the lower extent of tau pathology in aged P301SxTAU62on-off compared to P301Shet mice (see Supplementary 
Table 2 for complete values). Immunohistochemistry with TauC3 antibody did not reveal leakage of Δtau151-
421 expression in 16-months-old P301SxTAU62
on-off mice (Supplementary Fig. 4). A graphical representation 
of these findings can be found in Supplementary Fig. 2. 
We confirmed our histological findings by western blotting, using the human tau targeting HT7 antibody. 
Significantly higher levels of total (Fig. 4A, B) and soluble tau (Fig. 4C, D) were detected in P301Shet mice 
compared to P301SxTAU62on-off mice at 16 months of age (see Supplementary Table 2 for complete values). 
Next, we wanted to rule out that the mild motor phenotype as well as the comparatively mild tau pathology in 
aged P301SxTAU62on-off mice were caused by loss of human mutant P301S tau expression. To this end, we 
analyzed tau protein levels in these mice and their heterozygous littermates at the age of 3 months. Western 
blot analysis revealed comparable total tau levels in P301Shet and P301SxTAU62on-off mice (Fig. 5A, B; see 
Supplementary Table 2 for complete values). It is therefore unlikely, that the maintained motor competence of 
aged P301SxTAU62on-off mice occurs despite a potential previous loss of tau-expressing neurons in young 
paralyzed P301SxTAU62on mice. Nevertheless, based on Western blotting, discretely reduced tau expression 
levels in P301SxTAU62on-off compared to P301Shet mice cannot be excluded. Therefore, a mildly lowered tau 
expression might have been contributed to the slightly better motor performance and the less extensive tau 
pathology in aged P301SxTAU62on-off mice. In light of the extensive early tau toxicity occurring in 
P301SxTAU62on mice, an immunological reaction could also have been triggered by the toxic high molecular 
weight tau, and may have caused the lower tau levels in aged P301SxTAU62on-off mice. However, dot blot 
analysis did not detect any anti-tau antibodies in sera of 3-months-old P301Shet and P301SxTAU62on-off mice 





Brainstem homogenates from paralyzed P301SxTAU62on mice do not induce NFT formation in ALZ 17 
mice 
Our observations made so far argued against a long-term seeding effect of the early, non-fibrillar neurotoxic 
tau species which caused the severe motor palsy in P301SxTAU62on mice. To assess the seeding capacity of 
these non-fibrillar toxic tau species also in a classical tau seeding setting (Clavaguera et al., 2009), we next 
prepared brainstem homogenates from paralyzed 3-weeks-old P301SxTAU62on mice, and inoculated them 
intrahippocampally into 3-months-old ALZ17 tau transgenic mice. Brain homogenates derived from aged 
tangle-bearing homozygous P301S tau transgenic mice were used as positive controls, as these had previously 
been proven to provoke the formation of Gallyas-Braak silver stain-positive tangles when inoculated into 
ALZ17 mice (Clavaguera et al., 2009). As expected, ALZ17 mice seeded with P301S brainstem homogenates 
developed granular focal tau pathology, primarily in CA1 (Fig. 6A) and the ipsilateral dorsal fornix above CA1 
(Fig. 6B). In contrast, ALZ17 mice seeded with P301SxTAU62on brainstem homogenates remained devoid of 
Gallyas-Braak silver stain positive structures up to the age of 20 months. This observation indicates that the 
non-fibrillar toxic tau species associated with the severe paralysis of P301SxTAU62on mice are not seeding-







We here report that early neurotoxic tau stress causing severe motor paralysis in P301SxTAU62on mice is fully 
reversible and does not cause late seeding or adverse effects in recovered P301SxTAU62on-off mice during 
aging. Furthermore, we find that the inoculation of brainstem homogenates from paralyzed P301SxTAU62on 
mice into ALZ17 mice does not result in tau seeding in the host mice, demonstrating that non-fibrillar 
neurotoxic tau species can lack classical seeding competence.  
Co-expression of a tau151-421 with full-length P301S mutant tau in P301SxTAU62
on mice causes severe 
paralysis after three weeks, as we have previously reported (Ozcelik et al., 2016). This motor impairment is 
paralleled by an increase in hyperphosphorylated tau, but occurs in the absence of fibrillar tau forms or tau 
tangles. Upon switching off tau151-421 expression, hyperphosphorylated tau species are no longer detectable 
and P301SxTAU62on-off mice regain their motor function. This confirms that hyperphosphorylated non-fibrillar 
tau oligomers can mediate early neurotoxicity, and that clearance of these tau species rescues the paralyzed 
mice from their motor impairment (Ozcelik et al., 2016).  
While over-expression of non-aggregating tau deletion mutants lacks relevant neurotoxicity (Macdonald et al., 
2019), we here confirm that soluble oligomeric, yet non-fibrillar tau aggregates can exert extensive tau toxicity. 
This is also in line with reported clinical data: tau oligomers appear early in the brains of patients developing 
AD (Patterson et al., 2011; Lasagna-Reeves et al., 2012; Koss et al., 2016) and progressive supranuclear palsy 
(Gerson et al., 2014), possibly even before first clinical symptoms become apparent (Maeda et al., 2006). Tau 
oligomers have also been shown to correlate well with neurodegeneration in tau transgenic mice (Gomez-Isla 
et al., 1997; Lasagna-Reeves et al., 2011; Jiang et al., 2019). Based on this, oligomeric tau species are now 
considered to play a central role in the pathogenesis of neuronal dysfunction in tauopathies (Ghag et al., 2018; 
Polanco et al., 2018; Sengupta et al., 2018; Bittar et al., 2019), comparably to oligomeric structures in other 
neurodegenerative disorders (Hong et al., 2018; Sekiya et al., 2019). The severe early neurotoxic stress 
provoked by non-fibrillar tau forms in our P301SxTAU62on-off mice strengthens this view.  
Counterintuitively, we here find that P301SxTAU62on-off mice, which have been exposed to non-fibrillar 
neurotoxic tau, do not show an accelerated course of their tauopathy during aging. In contrast, aged 
P301SxTAU62on-off mice show rather better motor performance and less tau pathology in comparison to their 
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heterozygous P301S littermates, even though P301S tau expression remains unaffected upon switching off 
tau151-421 expression. To our knowledge, this is the first analysis of long-term consequences of early tau stress 
in a model maintaining the expression of an aggregation-prone tau form. Previous studies were conducted in 
mouse models conditionally expressing a single mutant human tau form, and the recovery of these mice was 
achieved by its suppression (Van der Jeugd et al., 2012; Polydoro et al., 2013; Wang et al., 2018). Thus, upon 
switch-off, aggregation-prone human tau forms were no longer expressed in these mice – a scenario, which 
does not reflect the situation of potential interventional tau clearance in man. In addition, previous studies in 
rTgTauEC mice have shown that NFT-associated toxicity can be reversed by suppressing tau overexpression 
(Polydoro et al., 2013). In pro-aggregant hTau40 transgenic mice, motor fitness improved after stopping 
mutant tau expression (Van der Jeugd et al., 2012). Similar results were obtained in PS19 mice by antisense 
oligonucleotide-mediated downregulation of mutant tau expression (DeVos et al., 2013; DeVos et al., 2017). 
An early study in rTg4510 mice has shown that tau tangle formation can be dissociated from neuronal 
dysfunction (Santacruz et al., 2005). In particular, cognitive functions recovered once expression of transgenic 
P301L tau had been halted, but tau tangles continued to accumulate (Santacruz et al., 2005). Our present 
findings now further separate tau toxicity from tangle formation by providing first evidence that early tau 
toxicity can be reverted even without subsequent seeding of fibrillar tau tangles. This indicates that halting tau 
oligomer-related toxicity prior to the appearance of filamentous tau can not only reverse clinical symptoms (as 
reflected by the motor phenotype recovery of our mice), but may also efficiently prevent long-term tau seeding 
and spreading. Strikingly, interventions with compounds targeting tau oligomers have already shown 
beneficial effects, including the reversal of brain dysfunction (Castillo-Carranza et al., 2014; Soeda et al., 
2015; Gerson et al., 2018; Lo Cascio et al., 2019; Lo et al., 2019). Our new findings suggest that early 
therapeutic tau oligomer removal might efficiently prevent the progression of tauopathies.  
We cannot exclude that the lack of a late tau seeding effect by early toxic tau species in aging P301SxTAU62on-
off mice is caused by immunological reactions targeting tau in these mice. The slower decline of motor function 
of recovered, aging P301SxTAU62on-off mice could also be associated with a protective mechanism triggered 
by the early neurotoxic tau stress. While a dot blot analysis of sera of P301SxTAU62on-off mice did not reveal 
any antibodies targeting recombinant tau, this does not fully rule out alternative immunological mechanisms 
(e.g. T-cell mediated; antibodies against specific epitopes of oligomeric tau assemblies). Furthermore, the 
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slightly lowered tau levels in aged P301SxTAU62on-off mice could also be a consequence of autophagy 
induction by the early oligomeric tau stress that these mice experienced; in support of the latter notion, it was 
previously found that pharmacological autophagy activation can defer tau pathology progression in P301S 
mice (Schaeffer et al., 2012; Ozcelik et al., 2013). 
As we cannot exclude that the lack of a late tau seeding effect by early toxic tau species in P301SxTAU62on-
off mice is attributable to immunological reactions or the induction of the autophagy pathway targeting 
oligomeric tau in these mice, we next investigated whether the early toxic tau species exert classical prion-like 
seeding competence upon intracerebral inoculation. Fibrillar tau induces the aggregation of soluble tau species 
in a prion-like manner upon inoculation into tau transgenic host mice (Clavaguera et al., 2009; Goedert et al., 
2017). We inoculated ALZ17 mice with brainstem homogenates from paralyzed P301SxTAU62on mice. These 
seeded ALZ17 mice remained completely free of fibrillar tau pathology up to high ages. In contrast, seedings 
with P301S brainstem homogenates induced focal granular Gallyas-Braak silver stain-positive tau aggregates, 
as these homogenates also contain short tau filaments, known to be the most seeding-competent tau species 
(Jackson et al., 2016). The absence of fibril induction in ALZ17 mice inoculated with brainstem homogenates 
from paralyzed P301SxTAU62on mice confirms that early toxic tau oligomers can lack fibrillar tau seeding 
competence.   
At late disease stages, seeding-competent tau structures are present in most tauopathies, and capable of seeding 
fibrillar tau aggregates when injected into ALZ17 mice (Clavaguera et al., 2013). Interestingly, the only 
homogenates not provoking the formation of Gallyas-positive fibrils in ALZ17 mice, comparable to our 
P301SxTAU62on brainstem homogenates, were extracts collected from argyrophilic grain disease (AgD) 
patients. This has been linked to the histological predominance of pre-tangles over fully formed tangles in AgD 
(Ferrer et al., 2008), similar to the pre-tangle stage pathology present in our paralyzed P301SxTAU62on mice. 
A low seeding activity of AgD extracts has recently also been found in an RT-QuIC in vitro seeding model 
(Kraus et al., 2019). In that study, also brain extracts from other tauopathies exerted only low seeding effects, 
demonstrating the presence of non-, or not-yet seeding-competent tau forms in human tauopathies including 
progressive supranuclear palsy (PSP) and corticobasal degeneration (CDB) (Kraus et al., 2019). A comparably 
low seeding efficacy of PSP and CDB homogenates was found in a cell-based aggregation assay, while seeds 
of AD patients resulted in high tau aggregation (Chung et al., 2019). In this light, our present findings warrant 
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caution when developing aggregation and seeding-based diagnostic assays. Very early tau forms could be 
toxic, but undetectable by seeding-based diagnostic tools.  
In conclusion, we here demonstrate that high molecular weight tau oligomers can provoke a severe, but 
reversible neurotoxicity. Rescued mice do not develop long-term sequelae, which argues for early therapeutic 
interventions targeting oligomeric tau forms. Furthermore, we confirm that these early toxic tau species lack 
classical seeding competence. Therefore, caution should be exercised when using seeding-based assays for the 
detection of very early preclinical tauopathy manifestations. Our findings also warrant a deepened analysis of 
early, non-fibrillar toxic tau forms in the future. While the knowledge on filamentous tau strains is rapidly 
growing thanks to Cryo-EM studies in particular (Fitzpatrick et al., 2017; Falcon et al., 2018a; Falcon et al., 
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Figure 1: Early neurotoxic stress depends on full length and ∆tau co-expression and is reversible.  
P301S heterozygous mice (P301Shet; n=5) at 21 days of age show no signs of paralysis in the tail 
suspension test, and histological tests with AT8 antibody did not detect hyperphosphorylated tau or 
Gallyas-positive tau fibrils in the tegmental reticular nucleus (A). Hindlimbs of P301SxTAU62on (n=5) 
mice the same age as their heterozygous littermates are paralyzed; upon histological characterization, 
paralyzed P301SxTAU62on mice show hyperphosphorylated tau but no Gallyas-positive tau fibrils in 
the same region (B). After suspending doxycycline administration for 3 weeks, P301SxTAU62on-off (n=5) 
mice recover their motor functions and do not show hyperphosphorylated or fibrillar tau (C). Altogether, 
the findings confirm that the severe neurotoxicity in P301SxTAU62on mice does not depend on 
filamentous tau pathology, but solely on hyperphosphorylated tau oligomers. Scale bar equals 75 µm, 












Figure 2: P301SxTAU62on-off mice do not develop an impaired motor phenotype upon aging.  
Tail suspension tests revealed normal hindlimb spreading for BL6 mice, and pathological hindlimb 
spreading predominantly in heterozygous P301S transgenic littermates at 16 months of age, while this 
was less pronounced in age-matched P301SxTAU62on-off (abbreviated P62on-off) mice (A). Rotarod test 
comparing BL6 (n=10), P301Shet (n=15), and P301SxTAU62on-off mice (n=13) at 16 months of age 
revealed that P301SxTAU62on-off animals were not significantly more impaired than P301Shet mice 
which did not undergo early neurotoxic stress (B, P-value = 0,14). Grid tests of BL6 (n=10), P301Shet 
(n=17), and P301SxTAU62on-off mice (n=11) at 16 months also showed that P301SxTAU62on-off mice 
were not experiencing heavier motor impairment when compared to their heterozygous littermates (C, 
P-value= 0,09). n.s. = P-value > 0,05; * = P-value < 0,05; ** = P-value < 0,01; *** = P-value < 0,001. 













Figure 3: Aged P301SxTAU62on-off mice show decreased hyperphosphorylated and fibrillar tau 
pathology compared to their heterozygous littermates.  
Histological tests comparing AT8 stained brainstem sections (A) of 16-months-old P301Shet (n=7) and 
P301SxTAU62on-off (abbreviated P62on-off) mice (n=7) revealed that the different performance in the 
behavioral tests was paralleled by different degrees of hyperphoshorylated tau pathology (B, P-value = 
3,39E-06). These results were also mirrored by Gallyas-stained brainstem sections (C) of 16-months-
old P301Shet (n=7), and P301SxTAU62on-off mice (n=7), which revealed different degrees of fibrillar 
tau pathology between the two groups (D, P-value = 7,77E-05). *** = P-value < 0,001. Scale bar equals 












Figure 4: Aged P301SxTAU62off mice show lower total and soluble tau levels than their 
heterozygous littermates.  
Western blot analysis of total tau (HT7 antibody) revealed that P301Shet mice (n=5) have a significantly 
higher level of total tau when compared to P301SxTAU62on-off (abbreviated P62on-off) mice (n=5) at 16 
months of age (A), which was confirmed by HT7/GAPDH ratio quantification (B, P-value = 1,32E-06). 
Soluble tau levels (C) in P301Shet mice (n=5) were also significantly higher than in P301SxTAU62on-
off mice (n=5), as reflected by HT7/GAPDH ratio quantification (D, P-value = 0,0001). *** = P-value < 






Figure 5: Total tau levels in young P301SxTAU62on-off mice do not decrease compared to their 
heterozygous littermates. 
Western blot analysis (HT7; A) and HT7/GAPDH ratio (B) for both P301Shet (n=6) and 
P301SxTAU62on-off (abbreviated P62on-off) mice (n=6). Tau levels were not significantly different 
between the two groups (P-value = 0,67). n.s. = P-value > 0,05. Box plots with hinges, whiskers and 
















Figure 6: Seeding with high molecular weight tau results in complete absence of fibrils in ALZ17 
mice. 
ALZ17 mice seeded with brainstem homogenates from paralyzed P301S homozygous (abbreviated 
P301Shomo) mice (n=5) revealed granular focal tau pathology in CA1 (A), which was not detected in 
ALZ17 mice seeded with P301SxTAU62on brainstem homogenate (n=4). Granular focal tau pathology 
was also found in the fornix (B), and Gallyas-positive structures were detected in ALZ17 mice seeded 
with brainstem homogenates of paralyzed P301Shomo mice, but not in ALZ17 mice seeded with 









2.2.1 Supplementary Material 
 
Supplementary Figure 1: 
 
 
Suppl. Fig. 1: High magnification images extending the findings shown in Figure 1.  
P301S heterozygous mice (P301Shet; n=5) at 21 days of age show no signs of hyperphosphorylated tau 
or Gallyas-positive tau fibrils in the tegmental reticular nucleus (A). Paralyzed P301SxTAU62on mice 
(n=5) show hyperphosphorylated tau but no Gallyas-positive tau fibrils in the same region (B). After 
suspending doxycycline administration for 3 weeks, P301SxTAU62on-off mice (n=5) do not show 






Supplementary Figure 2: 
 
 
Suppl. Fig. 2: Schematic of background and main conclusions showing no long-term sequelae of 
reverted tau toxicity.  
P301SxTAU62on mice co-express human P301S mutant tau and, only under oral doxycycline (DOX) 
administration, ∆tau151-421 fragment. This results in hyperphosphorylated tau oligomers that cause a 
severe paralysis after 21 days. If these mice are fed normally, they only express heterozygous mutant 
P301S tau but not the tau fragment, and are thus comparable to P301Shet mice which remain without 
oligomeric tau formation or severe paralysis after 21 days. After expression of the doxycycline-
responsive ∆tau151-421 fragment is switched off (P301SxTAU62
on-off), hyperphosphorylated tau oligomers 
are cleared efficiently and mice recover their motor function in the following 3 weeks, even though 
mutant P301S tau expression is being maintained. Therefore, P301SxTAU62on-off mice exhibit a similar 
phenotype as P301Shet mice at three months of age. At 16 months of age, P301SxTAU62on-off mouse 




tau oligomers are significantly less abundant in P301SxTAU62on-off compared to P301Shet mice. This 
proves that P301SxTAU62on-off mice do not experience sequelae of the early neurotoxic stress, when 
compared to their heterozygous P301S tau transgenic littermates. 
 
Supplementary Figure 3:  
 
Suppl. Fig. 3: High magnification images extending the findings shown in Figure 3.  
Aged P301SxTAU62on-off mice exhibit less AT8 and Gallyas-positive neurons than their heterozygous 
littermates. AT8 (A) and Gallyas silver (B) stained brainstem sections of 16-months-old P301Shet mice 
(n=7) show more hyperphosphorylated tau and silver stain positive pathology than P301SxTAU62on-off 






Supplementary Figure 4:  
 
Suppl. Fig. 4: Immunohistochemistry targeting the AT100 phospho-epitopes at Thr 212 and Ser 214, 
and ∆tau (TauC3 antibody) in 16-months-old mice.  
In parallel to Gallyas silver stain positivity (Suppl. Fig. 3), extensive hyperphosphorylation of AT100-
positive tau was seen in the brainstem of heterozygous P301S littermates (n=7) (A), but was almost 
absent in P301SxTAU62on-off mice (n=7) (C). Immunohistochemistry with TauC3 antibody did not find 
any tau fragment in non-fragment expressing P301Shet mice (n=7) (B), nor were signs of fragment 
expression leakage detectable in P301SxTAU62on-off mice (n=7) (D). The scale bar corresponds to 100 
μm, and applies from A to D. 
 
Supplementary Figure 5:  
 
Suppl. Fig. 5: 3-months-old P301Shet and P301SxTAU62on-off mice do not show anti-tau antibodies in 
their sera.  
Dot blot with the sera of 3-months-old P301Shet (n=4) and P301SxTAU62on-off (labelled P62 on-off; n=3) 
mice was conducted, to test for the presence of anti-tau antibodies, using HT7 antibody as a positive 






Supplementary Figure 6:  
 
Suppl. Fig. 6: Schematic of background and main conclusions showing that oligomeric toxic tau species 
can lack seeding competence.  
As positive control, ALZ17 mice were injected with tau fibril-containing brainstem homogenates of 
paralyzed, 6-months-old P301S mice (left box). These ALZ17 control mice developed granular focal 
tau pathology in the injected hippocampus. Next, we analyzed the seeding capacity of oligomers 
resulting from co-expression of P301S tau and ∆tau151-421. To this end, we inoculated ALZ17 transgenic 
mice with brainstem homogenates collected from paralyzed, 3-weeks-old P301SxTAU62on mice, which 
do not show fibrillary tau pathology (right box). ALZ17 mice seeded with P301SxTAU62on mice 
brainstem homogenates did not develop focal tau aggregates in the inoculated hippocampus. This proves 






Supplementary Table 1:  
TEST Mean time ± 
STD BL6  
Mean time ± 
STD  
P62on-off  









BL6               vs  
P62on-off 
P-value  




33 s ±  
8,77 s 
17,46 s ±  
12,78 s 
 












81,9 s ±  
65,14 s 
40,27 s ±  
38,84 s 











Suppl. Table 1: Overview on behavioral tests.  
The table shows the overview of the statistical values of the behavioral tests executed on P301S 
heterozygous mice (P301Shet), P301SxTAU62on-off mice (P62on-off) and BL6 mice; n.s = P-value > 0,05; 






Supplementary Table 2:  
TEST Mean ± STD 
P301Shet 
Mean ± STD 
P62on-off 








0,50 ± 0,19 0,07 ± 0,04 7,77E-05 
(***) 
HT7/GAPDH signal total tau 
WB  16 months 
4,51 ± 0,24 2,88 ± 0,15 1,32E-06 
(***) 
HT7/GAPDH signal soluble 
tau 
WB 16 months 
3,23 ± 0,39 1,71 ± 0,31 0,0001 
(***) 
HT7/GAPDH signal 
WB 3 months 
5,03 ± 1,11 4,81 ± 0,67 0,67 
(n.s) 
 
Suppl. Table 2: Overview on immunohistochemistry and western blots.  
The table shows the overview of the statistical values of the quantified stained sections and western blots 
on 3 and 16 months old P301S heterozygous (P301Shet) mice and P301SxTAU62on-off (P62on-off) mice; 











3 Supplementary Results 
 
 
3.1 Sup35NM is able to promote the vascular aggregation of 
amyloid-beta (Aβ) 
 
After the promising results of our study “Cross-seeding of Alzheimer-related prion-like proteins 
by non-mammalian prions” where we investigated the potential of Sup35NM fibrils to 
accelerate the aggregation of tau in vitro and in vivo, we decided to also investigate the 
potential of Sup35NM fibrils to accelerate the formation of amyloid-beta (Aβ) aggregates. 
Strikingly in a first trial the inoculation of App23 mice, expressing human amyloid precursor 
protein (APP) bearing the pathogenic Swedish mutation (Sturchler-Pierrat et al., 1997), led to 
the accelerated formation of vascular Aβ aggregates in the hippocampus of the mice specific 
for the brain half of the Sup35NM inoculation. The results are shown below in figure 4. The 
difference between injected and non-injected hippocampal side was stronger after an 
increased time of incubation. While after 14 months of incubation the difference in Aβ 
deposition was mainly quantitative (fig. 4b) after 19 months of incubation the affected vessels 
were mostly filled with Aβ aggregates on the injected brain halve while on the non-injected 
brain halve the deposition of Aβ was mainly limited to the vessel walls (fig. 4a). Compared to 
seeding with Sup35NM, seeding of App23 mice with -5TyrSup35NM monomers only led to a 
very limited increase in Aβ aggregation (fig. 4c). This is in coherence with our results for the 
seeding potential of Sup35NM and -5TyrSup35NM concerning tau aggregation where -
5TyrSup35NM also only showed a mild residual tau aggregation induction capacity. This is 
further evidence, that structural similarities, in this case the presence of an in-register beta 
sheet structure in Sup35NM, Aβ and tau aggregates, are necessary for an efficient prion 
seeding effect. This is also in line with recent scientific results by others, showing that 
aggregates, but not monomers, of Aβ, tau, and α-synuclein bind to PrP (Corbett et al., 2019).  
Altogether these preliminary results about Sup35NM and its ability to seed Aβ aggregation 
support our hypothesis of a structure based prion seeding of prion-like proteins like tau and Aβ 
as a potential way on how a natural prion from the human microbiome like Sup35 can influence 






Figure 4: Sup35 seeds Aβ aggregation in App23 mice 
a-c, increase in immunohistochemistry (Anti Aβ antibody; Agilent, Cat# M0872) positive vascular Aβ 
deposits in the hippocampal CA1 field following unilateral intrahippocampal Sup35NM fibril inoculation 
(a-b) or -5TyrSup35NM monomer inoculation (c) in App23 Aβ transgenic mice.  Comparison of the non-
injected side (contralateral) to the injected side (ipsilateral) in representative histological findings 
(Bregma level -2.4mm) after 19 months of incubation with Sup35NM (a), 14 months of incubation with 








3.2 Modulating tau toxicity by Cabazitaxel  
 
Cabazitaxel is a taxane which was shown to be able to pass the blood brain barrier (BBB) two- 
to three-fold better than the taxanes docetaxel and paclitaxel. Additionally, Cabazitaxel is 
distributed well throughout the brain parenchyma and has a way longer retention time in the 
mouse brain than in the mouse blood (Cisternino et al., 2003; Girard et al., 2015). This makes 
it an ideal candidate drug for the approach to stabilize microtubules in the brain while 
minimizing the likelihood of side effects. In AD tau gets hyperphosphorylated and leaves the 
microtubules, which leads to microtubule destabilization and therefore to a disturbance of 
axonal transport (Kadavath et al., 2015). In accordance with this the taxane epothilone D 
(EpoD) was able to reduce axonal dysfunction in the PS19 mouse model of tauopathy (Zhang 
et al., 2012). However, a clinical Phase 1 trial to evaluate the tolerability and pharmacology of 
EpoD was discontinued (ClinicalTrials.gov Identifier: NCT01492374). P301SxTAU62on mice 
exhibit extensive signs of axonal transport disruption (Ozcelik et al 2016). This renders them 
particularly suitable for the analysis whether microtubule stabilizing agents can rescue tau 
oligomer induced axonal transport failure.  
Additionally, due to the rapid onset of motor impairments in P301SxTAU62on mice, significant 
behavioral responses can be measurable already within 3 weeks after initiation of treatment. 
Against this background, we assessed the microtubule stabilizer Cabazitaxel.  
In order to first examine potential side effects of Cabazitaxel we started the treatment with a 
low dose of 1mg/kg. Cabazitaxel was solved in a solution consisting of 5% ethanol, 5% 
polysorbate and 90% aqueous solution containing 5% sucrose. This is the same application 
vehicle which is used in the treatment of human cancer patients with Cabazitaxel (Lazzarini et 
al., 2015). For the first trial 3 mice were injected with Cabazitaxel, 2 mice with vehicle only and 
2 mice served as uninjected controls. The mice were injected once a week for three weeks. 
With these doses there were no visible side effects for mice injected with Cabazitaxel 
compared to mice, with the same genotype, which were injected only with the vehicle or not 
injected at all. However, unfortunately the treatment with Cabazitaxel also did not result in any 
phenotypical slowing of the developing paresis. Therefore, and for the absence of side effects, 
we decided to increase the dosage of Cabazitaxel to 2mg/kg bodyweight. For this second trial 
6 mice were injected with Cabazitaxel, 6 mice with vehicle only and 3 mice served as 
uninjected controls. While again not seeing any side effects there was again no visible 





As the clinical trial to evaluate the tolerability and pharmacology of EpoD in humans was 
stopped with doses between 0.01 mg/kg and 0.003 mg/kg, we considered that the risk of 
harming the test mice by further increasing the dosage of Cabazitaxel would outweigh the 
chance of potential benefits compared to control mice. Therefore, we decided to discontinue 
our trials with Cabazitaxel in order to adhere to the 3R principles of animal ethics.  
After our decision to discontinue our experiments with Cabazitaxel the results of a Phase 1 
trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary 
efficacy of Cabazitaxel (taxane TPI-287) in AD patients were published (Tsai et al., 2019). This 
trial had been completed in November 2019 (ClinicalTrials.gov Identifier: NCT01966666). In 
this study treatment with TPI-287 led to severe anaphylactoid reactions, more falls and a dose-
related worsening of dementia symptoms (Tsai et al., 2019). These results show that our 




























Homozygous human P301S mutant tau transgenic mice (P301S tau mice) (Allen et al., 2002) 
were used as host mice for  tau seeding experiments with Sup35NM. Heterozygous App23 
mice overexpressing mutant human amyloid precursor protein (APP) bearing the pathogenic 
Swedish mutation (Sturchler-Pierrat et al., 1997) were used for amyloid beta (Aβ) seeding 
experiments with Sup35NM. Transgenic homozygous mice expressing human ALZ17 mutant 
tau (ALZ17 mice) (Probst et al., 2000) were used as host mice for  tau seeding experiments 
with brain stem homogenates from P301SxTAU62 mice. P301SxTAU62 mice were obtained 
by interbreeding P301S mice and TAU62 mice (Ozcelik et al., 2016). TAU62 mice express a 
human tau fragment from amino acid 151-421 (Δtau) (Ozcelik et al., 2016). P301SxTAU62 
mice were used for the investigation of potential long-term effects of neurotoxicity caused by 
tau oligomers, and for the Cabazitaxel trials. The mice were housed with a 12-h light/dark cycle 
and permanent access to food and water. Animal experiments were approved by the official 
local Committee for Animal Care and Animal Use of the Canton of Basel (Licenses Nr. BS 
2364 and 2471). 
 
4.2 Stereotaxic surgery 
 
Three months-old P301S tau and App23 mice were anaesthetized with a mixture of ketamine 
(10 mg/kg) and xylazine (20 mg/kg) and placed on a heating pad to maintain body temperature 
during surgery. Mice were injected in the right hippocampus (A/P, −2.5 mm from bregma; L, − 
2.0 mm; D/V, −1.8 mm) using a Hamilton syringe. Each mouse received a unilateral stereotaxic 
injection of 2.5 μl volume, at a speed of 1.25 μl/min. Following the injection, the needle was 
kept in place for an additional 3 min. The surgical area was cleaned with saline and the incision 
sutured. Mice were monitored until recovery from anesthesia, provided analgesic medication 
post-surgery, and checked regularly following surgery. Alz17 were operated under the same 








4.3 Tissue homogenization 
 
Brainstem homogenates of 6-months old paralyzed homozygous P301S mice, 3-weeks old 
paralyzed P301SxTAU62on mice and C57BL/6 mice (B6 mice) were prepared for later 
inoculation in P301S, App23 or ALZ17 mice.  
Brainstems were weighted and diluted 1:9 in PBS for seeding and TBS-Complete for Western 
blots. For both procedures, after dilution, the samples were homogenized using an Ultraturrax 
T8 (IKA labortechnik, Staufen im Breisgau, Germany) and briefly sonicated (Bandelin 
SONOPULS, 90% power, 10% cycle, 10 sec pulses). The homogenates were then centrifuged 
at 4000 g for 20 minutes, at 4 °C, and the aliquots of the resulting supernatant were stored at 
-80 °C for later usage. 
 
4.4 Expression, purification and fibrillization of Sup35NM 
 
The combined N-terminal (N) and middle (M) domains of Sup35 are sufficient to form 
Sup35NM fibrils harboring prion properties (Sparrer et al., 2000). The Sup35NM expression 
plasmid p1404 was a kind gift from Prof. Reed B. Wickner (Laboratory of Biochemistry and 
Genetics, NIH, Bethesda, U.S.A.). E. coli Rosetta (DE3) pLysS was used as expression host. 
The transformation of the E. coli was performed using the heat shock method (Froger and Hall, 
2007). Transfected cells were selected using LB plates containing Ampicillin (50 µg/ml) and 
Kanamycin (30 µl/ml). A transformed colony was incubated overnight at 37 °C in a 50 ml LB-
ampicillin-kanamycin flask. On the next day 20 ml of growing culture were added to a fresh 
flask containing 2L TB-ampicillin-kanamycin medium.  
Induction was performed with 1 mM Isopropyl β-d-1-thiogalactopyranoside (IPTG) at an optical 
absorption at 600 nm wavelength (A600) of approx. 1. The cells were harvested after 5h of IPTG 
induction. The cell pellets were collected by centrifugation and lysed by sonication in lysis 
buffer (50 mM Tris-HCL, 1 mM phenylmethylsulfonyl fluoride (PMSF), 8 M urea, pH 8.0).  
The lysate was cleared using centrifugation at 12,000 g for 20 min at 4 °C. The cleared 
supernatant was applied to a 1 ml HisTrapTM (GE Healthcare, Chicago, US) column pre-
equilibrated with lysis buffer. The column was washed with wash buffer (50 mM Tris-HCl, 1 
mM DTT, 8 M urea, 300 mM NaCl and 20 mM imidazole) until the absorption at 280 nm 
reached zero. The target protein was eluted using 250 mM imidazole. The protein in each 
fraction was monitored using a spectrophotometer. The purity of Sup35NM in the selected 




The protein was then loaded onto a HiLoad 16/60 Superdex 75 PG (GE Healthcare, Chicago, 
US) column equilibrated with 7 M urea, 50 mM Tris (pH 7.5) and 150 mM NaCl.  
The fractions containing Sup35NM were assessed via WB using an anti His-Tag antibody 
(Anti-6X His tag® antibody (HRP), Abcam, Cambridge, UK), pooled, concentrated and 
dialyzed against PBS using a Slide-A-Lyzer 10K dialysis cassette (Thermo Fisher Scientific, 
Waltham, US). Sup35NM was then concentrated to 0.271 mg/ml using an Amicon ultra-
centrifugal filter with a 10K cutoff (Millipore, Burlington, US). Afterwards, Sup35NM was placed 
in a cold room at 4 °C under slight agitation for 3 days in order to enable fibrillization into the 
desired conformation (Ohhashi et al., 2010). Aliquots of fibrilized samples were stored at -80 
°C prior to the inoculations.    
 
4.5 Preparation of -5TyrSup35NM and Cabazitaxel 
 
-5TyrSup35NM was obtained from GenScript (Piscataway, US), diluted in PBS solvent to a 
concentration of 0.3 mg/ml and stored at -80 °C prior to the inoculation. Cabazitaxel was 
obtained from Lucerna-Chem AG (Luzern, CH) and solved in a solution consisting of 5% 
ethanol, 5% polysorbate and 90% aqueous solution containing 5% sucrose. 
 
4.6 Behavioral tests 
 
Motor behavior, including gait ataxia, tremor and hind limb reflexes, was assessed. 
Quantitative motor testing was performed by the grid test in which mice were placed on a 
vertical mesh grid and the latency to fall off from the grid was recorded for 3 min. The motor 
coordination and balance of mice were assessed using the Panlab Harvard Rotarod (Panlab, 
Barcelona, ES). The Rotarod starts at a speed of 4 rpm and accelerates consistently with 1 
rpm every 3 sec. For both tests, the mice were tested for 3 consecutive days with 3 trials each 
day and a rest interval of 5 min minimum, and the mean latency to fall was documented. 
Results were obtained by averaging the daily means of 3 consecutive days, and the daily 







4.7 Sacrificing of mice and tissue preparation 
 
Mice were deeply anaesthetized with a mixture of 2% Rompun (5 mg/kg) / 10% Ketamin (100 
mg/kg) 0.2 ml / 10 g body weight i.p. using a 25G hypodermic needle. Once in deep narcosis 
and no longer responding to stimuli, the mice were transcardially perfused with 20 ml cold 
PBS, followed by 20 ml 4% paraformaldehyde in PBS. The brains were dissected and post-
fixed overnight. Following paraffin embedding, 4 μm coronal sections were cut from the brain 
tissues of seeded mice, while 4 μm sagittal sections were cut from the brain tissues of the mice 
used for the behavioral tests. For Western blots and seeding material, the mice were only 
perfused with PBS, afterwards mouse brains were dissected and frozen in liquid nitrogen or 
on dry ice. 
 
4.8 Hematoxylin and Eosin staining 
 
Paraffin tissue sections were deparaffinized in xylene for 30 min and rehydrated through a 
series of EtOH/water solutions from 100 %, 96 %, 80 %, and 70 %, followed by dH2O, 
submerging the sections for 2 min each step. The rehydrated sections were stained with Harris’ 
hematoxylin (J.T. Baker, Biosystems Switzerland AG, Muttenz, CH), for 0.5 min, washed twice 
in dH2O and differentiated in 0.2 % HCl diluted in 70 % ethanol. Afterwards the Sections were 
stained in 1 % Erythrosine B (RAL DIAGNOSTICS, Biosystems Switzerland AG, Muttenz, CH), 
a stain closely resembling eosin Y, washed in dH2O and dehydrated through an ascending 
series of EtOH water solutions, form 70 %, 80 %, 100 %, followed by xylene. Subsequently the 
sections were mounted using Pertex (Histolab Products AB, Biosystems Switzerland AG, 
Muttenz, CH). 
 
4.9 Gallyas silver staining 
 
Tissue sections were silver-impregnated following the method of Gallyas-Braak to visualize 
filamentous tau pathology (Gallyas, 1971; Braak et al., 1988). Paraffin tissue sections were 
deparaffinized and rehydrated as described above. Afterwards the sections were incubated in 
3 % periodic acid (w/v) for 30 min, rinsed in dH2O and incubated in alkaline silver solution (1 





Subsequently the sections were developed by mixing developer solution 1 (0.5 M Na2CO3), 
solution 2 (24 mM NH4NO3, 12 mM AgNO3, 3.5 mM H4[Si(W3O10)4]), and solution 3 (24 mM 
NH4NO3, 12 mM AgNO3, 3.5 mM H4[Si(W3O10)4], 3 % formaldehyde) in a ratio of 30:9:21 
immediately before use, the sections were developed for ca. 25 min, simultaneous to 
monitoring of the reaction process.  
The developing was stopped via incubation in 0.5 % acetic acid for 30 min and fixed via 
incubation in 5 % Na2S2O3 for 3 min. The silver stained sections were rinsed in dH2O, 
counterstained using hematoxylin and Eosin, differentiated, dehydrated, and embedded as 
described on the previous page.  
 
4.10 Immunohistochemistry and Western blots 
 
For tau immunohistochemistry, the monoclonal antibodies AT8 (1:1000, Thermo Scientific, 
Waltham, US), and HT7 (1:1500,  Thermo Scientific, Waltham, US) were used as described 
previously (Ozcelik et al., 2016). For Aβ immunohistochemistry M0872 antibody (1:10 Agilent 
Technologies, Santa Clara, US) was used. Paraffin tissue sections were deparaffinized and 
rehydrated as described for Hematoxylin and Eosin staining. For epitope retrieval the slides 
were placed in ProTaqs citrate buffer with pH 6 (BIOCYC, Potsdam, DE) and microwaved for 
30 min. at 90 °C.  The secondary antibodies and peroxidase (HRP) substrate were from Vector 
Laboratories, Burlingame, CA (Vectastain ABC kit) and used according to manufacturer's 
protocol.  
For seedings with Sup35NM, -5TyrSup35NM and brain homogenate from B6 mice, for 
quantification of the CA3 region (Lorente de Nó, 1934), a total of 3 brain tissue sections were 
analyzed (at levels -2.6 mm, -2.4 mm and -2.2 mm from Bregma) per mouse and staining. 
Bregma levels were determined by visual comparison with the Mouse Brain Atlas (Franklin and 
Paxinos, 2007). The number of AT8 positive neurons and Gallyas-Braak silver stained neurons 
was counted by two raters (M.F., A.M.) on 10X magnified, randomly labelled images, taken 
with a BX43 Upright Microscope (Olympus, Shinjuku, Japan). The mean of the neuron 
numbers obtained by the two raters was used for statistical analysis.  
For a few stainings, only 2 sections next to the indicated Bregma levels were well preserved 
and usable for quantification (4 sections lacking for AT8 stainings, 3 sections lacking for the 
Gallyas-Braak stainings). Due to fixation artifacts, which interfered with immunohistochemistry 
but not with Gallyas-Braak silver staining, AT8 immunohistochemistry was not quantifiable for 




For Western blots brain tissue was homogenized as described in 3.3. Western blots were then 
performed under non-reducing conditions by using samples composed of an appropriate 
amount of protein, 4X NuPAGE LDS sample buffer (Thermo Scientific, Waltham, US) and 
deionized water. Additional application of 10X NuPAGE reducing agent (Thermo Scientific, 
Waltham, US) was used to obtain reducing conditions. 
 
4.11 Dot blots 
 
For dot blots, serum of 3-months-old P301Shet and P301SxTAU62on-off mice was separated 
from the clot by centrifuging the samples at 1000 rpm for 15 minutes at 4 °C, with the remaining 
supernatant aliquoted and stored at -20 °C, for later usage. Then, a nitrocellulose membrane 
(Bio-Rad Laboratories, Inc., Hercules, USA) was divided in a grid to allow later incubations 
with 3-months-old P301Shet and P301SxTAU62on-off sera and HT7 antibody as positive 
control at 1:1000 dilutions. 0.2 mg/ml of 2N4R wild-type tau monomers were applied on a 4x3 
grid. Next, unspecific binding epitopes were blocked with 5% BSA in PBS-Tween, followed by 
a 30-minutes-long incubation at room temperature with previously extracted sera from the mice 
and HT7 antibody as positive control. After washing with PBS-Tween, the membrane was 
incubated with HRP-conjugated anti-mouse secondary antibody at room temperature, washed 
again in PBS-Tween, and detected by ECL (GE Healthcare, Little Chalfont, UK). 
 
4.12 Statistical analysis 
 
 
Statistical analysis for the project “Cross-seeding of Alzheimer-related prion-like 
proteins by non-mammalian prions” 
 
We first compared the ipsilateral (inoculated) side to the contralateral (non-inoculated) side of 
Sup35NM injected mice. In order to estimate the number of AT8 or Gallyas-Braak stain positive 
neurons in their hippocampal CA3 fields, the mean neuron counts per mouse of the ipsilateral 
side were compared by paired T-tests to the contralateral side.  
Next, the estimated mean neuron counts per mouse in the ipsilateral CA3 field of P301S tau 
transgenic mice inoculated with either B6-bh, -5TyrSup35NM or Sup35NM were compared.   




P-values were adjusted for multiple comparisons using Tukey’s test. A p-value < 0.05 was 
considered as significant. All evaluations were done using the statistical software "R" (www.r-
project.org). Mean values and standard deviations are shown in figures. 
 
Statistical analysis for the project “Severe oligomeric tau toxicity can be reversed 
without long-term sequelae” 
 
To evaluate behavioral test results statistically, one-way analysis of variance (ANOVA) 
followed by post-hoc Student’s t-tests and Bonferroni correction for multiple comparisons were 
applied. P-values < 0.05 were considered significant. To estimate soluble tau and total tau 
expression from western blots of 3-months-old and 16-months-old mice, the protein bands 
were normalized to GAPDH protein standard, and quantified using ImageJ software; generated 
mean ratio values were compared by Student’s t-test. To determine the effect of early 
neurotoxic stress in aged mice, AT8 and Gallyas-positive neurons were semi-quantitatively 
assessed in brainstem regions. Three sections per animal were analyzed. The total area 
analyzed per animal was comparable between animals (AT8: P-value = 0,34, and Gallyas: P-
value = 0,91). The average count/area ratios were obtained. P-values calculated by Student’s 
t-tests were interpreted exploratory and not adjusted for multiple comparisons; P-values < 0.05 
were considered significant. Box plots for figures 2 to 5 were generated with R software. The 
lower and upper hinges correspond to the first and third quartiles (25th and 75th percentiles). 
The upper whisker extends from the hinge to the largest value no further than 1.5 times IQR 
from the hinge (where IQR is the inter-quartile range, or distance between the first and third 
quartiles). The lower whisker extends from the hinge to the smallest value at most 1.5 times 








4.13 In vitro seedings 
 
For in vitro seedings, recombinant 2N4R wild-type tau (ab84700, Abcam (Cambridge, UK)) 
and recombinant 2N4R P301S mutant tau (009-001-U01, Rockland Immunochemicals Inc. 
(Limerick, US)) were used together with the Sup35NM seeds and -5TyrSup35NM monomers 
described under 3.4 and 3.5. 
The buffer of tau monomers was exchanged to Dulbecco's phosphate-buffered saline (DPBS) 
without calcium and magnesium (D8537, Merck KGaA (Darmstadt, D)) with the use of 
Microspin™ G-50 columns (GE27-5330-01, GE Healthcare (Chicago, US)). 
Sup35NM seeds were created from filaments by sonication (cycle: 0.2 s, amplitude: 100%, 4x 
20 s with 2 minutes breaks in between) in a UP200St tube sonicator (Hielscher Ultrasonics 
GmbH (Teltow, D)). The seeds were filtered with 0.22 µm filter centrifuge tubes to exclude 
longer filaments. 
Tau monomers at a final concentration of 0.1 mg/ml were mixed with 0.027 mg/ml of seeds in 
DPBS containing 0.02% sodium azide and 0.02 mg/ml heparin (H3393, Merck KGaA 
(Darmstadt, D)). Samples were incubated at 37 °C on an overhead rotator at 30 RPM. Seeding 
experiments were replicated three times. 
Seeds from Sup35NM induced 2N4R wild-type tau filaments were created by sonication in a 
similar manner as described above (cycle: 0.2 s, amplitude: 100%, 4x 5 minutes with 5 minutes 
breaks in between). Tau seeds were diluted 1:3 in 2N4R wild-type tau monomers for re-
seeding experiments. 
 
4.14 Transmission electron microscopy 
 
The in vitro samples were negatively stained and studied by transmission electron microscopy 
(TEM) at different time points. 4 µl of sample were adsorbed for 60 s on glow-discharged 
copper grids that were coated with 2% parlodion and a continuous carbon film.  
Samples were blotted with filter paper, washed in three drops of distilled water and stained 
with 2 droplets of 2% uranyl acetate solution for 20 s, followed by blotting and air-drying.  
Labelling of tau filaments with immuno-gold was adapted from Goedert et al. (Goedert et al., 
1992). Samples were adsorbed on TEM grids as described before. Grids were laid face down 
on a drop of 0.1% gelatin (G7041, Merck KGaA (Darmstadt, D)) in DPBS and incubated for 10 
min at room temperature. The grids were blotted with filter paper and transferred to a droplet 
of HT7 anti-tau antibody (MN1000, Thermo Fisher Scientific (Waltham, US), 1:20 dilution in 




After blotting and washing in 3 drops of gelatin solution the grid was placed on a droplet of 
anti-mouse antibody conjugated to 10 nm gold beads (EM. GAF10, BBI Solutions (Crumlin, 
UK)) and incubated for 60 min at room temperature. The grid was blotted and negatively 
stained with two droplets of uranyl acetate as described above. 
Samples were imaged with FEI Tecnai T12 (operated at 120 kV) and FEI Tecnai G2 Spirit 
(operated at 80 kV) transmission electron microscopes (Thermo Fisher Scientific (Waltham, 
US)) equipped with TVIPS TemCam-F416 (Tietz Video and Image Processing Systems GmbH 
(Gauting, D)) and EMSIS VELETA (EMSIS GmbH (Münster, D)) cameras, respectively. 
Measurements on the electron micrographs were done with the imageJ distribution Fiji 
(https://fiji.sc/). For Sup35NM seeded 2N4R wild-type tau, periodicity of the wave pattern was 





Compound Concentration Supplier 
Tris 100 mM (pH 8.5) Biomol  
EDTA 5 mM Fluka BioChemika 
NaCl 200 mM Merck  
SDS 0.2% Bio Rad  
 
For sample digestion the thermo shaker was set at 55 °C and 750 µl of tense buffer and 3,75µl 
of Proteinase K were added to each sample. The samples were incubated overnight (or at 
least for 4 hours) at 55 °C and 600 rpm.  
For DNA Isolation the samples were centrifuged at 4 °C and 14000 g for 5 min. A new tube for 
each sample was labelled and filled with 750 µl of isopropanol. Subsequently the supernatant 
was taken from each sample and added to the respective isopropanol tube. The tubes were 
then centrifuged at 4 °C and 14000 g for 10 min.  
Afterwards the supernatant was discharged and 200 µl of 75% ethanol were added to each 
pallet. Next the samples were centrifuged at 4 °C and 14000 g for 10 min. Afterwards the 
supernatant was discharged and 250 µl of sterile water were added to each tube. Subsequently 




For PCR 2.5 µl of each DNA sample were added to a PCR tube containing 22.5 µl of PCR mix 
(see first table below). The primers and PCR programs for the Δtau allele and 4R tau allele 
(P301S tau detection) are sown below and on the next page. 
For Gel electrophoresis 3 gels were prepared by mixing 300 ml of TAE-buffer with 4.5g of 
agarose in an Erlenmeyer Flask and heating the mixture in the microwave at maximum temp. 
for 4 min. Afterwards the mixture was cooled down for a couple minutes and 15 µl of cyber 
save were added. 3 comps were placed in the gel chamber and the chamber was filled with 
the liquid gel. After solidifying the resulting gel was cut into 3 gels. For immediate use the gels 
were put in an electrophoresis chamber filled with TAE-buffer, 5 µl of loading dye were added 
to each sample and the samples were loaded to the gel. The gel was run in TAE-buffer for 60 
min. at 150V (90 min. at 150V if the gel is run in TBE-buffer). For storage the gels were stored 
in TAE-buffer at 4 °C in the fridge.  
 
PCR mix 
12,5 µl Qiagen PCR Master mix Qiagen 
4 µl sterile water Qiagen 
2,5 µl forward primer Thermo Scientific 
2,5 µl reverse primer Thermo Scientific 




Primer names Forward primer  Reverse Primer 
TauF151 (for Δtau detection) GTG GAT CTC AAG CCC 
TCA AG 
GGC GAC TTG GGT GGA 
GTA 
P301S (for 4R tau detection) GGT TTT TGC TGG AAT 
CCT GG 











TauF151 program P301S program 
Step 1: 95°C for 2 min Step 1: 95°C for 4 min 
Step 2: 95°C for 1 min Step 2: 95°C for 1 min 
Step 3: 60°C for 1 min Step 3: 60°C for 1 min 
Step 4: 72°C for 2 min Step 4: 72°C for 3 min 
Step 5: 72°C for 10 min (final extension) Step 5: 72°C for 10 min (final extension) 


























The aging of society was associated with a rapid increase in people suffering from dementia 
with Alzheimer disease (AD) as its predominant form. The case numbers of AD have increased 
from a few cases per country at the beginning of the 20th century to a current state where every 
7 seconds somebody in the world is diagnosed with AD (Cornutiu, 2015) and these numbers 
are predicted to continue their dramatic increase in the near future (Gaugler et al., 2016). 
Between 2000 and 2018, deaths resulting from stroke, and heart disease decreased in the US, 
while reported deaths from AD increased by 146.2% (‘2020 Alzheimer ’ s disease facts and 
figures’, 2020). In AD and other neurodegenerative proteinopathies with amyloid aggregation 
most of the cases appear sporadic. To find the original cause for AD and other neurological 
diseases would be an extremely important step towards a better understanding of the 
pathological mechanisms of said diseases and an enormous help for the development of 
preventive or curative approaches. Tau is a hallmark protein of AD and other neurological 
diseases called tauopathies. Several studies have shown, that tau has prion-like properties, it 
was therefore termed a prionoid (Scheckel and Aguzzi, 2018). In tauopathies caused by a 
specific genetic background, disease associated mutations increase the ability of tau to 
aggregate and build amyloids. The resulting amyloid fibers consist of ordered protein 
assemblies with abundant cross beta sheet structures (Barghorn et al., 2000; Knowles, 
Vendruscolo and Dobson, 2014). This supports the idea of tau aggregation as a crucial step 
in pathogenesis. Moreover tau deposition predicts brain atrophy in AD patients with the 
strongest correlation being found in young patients (La Joie et al., 2020). Additionally, in 
seeding trails with transgenic mice, tau stains with different conformations caused different 
levels of pathology (Kaufman et al., 2016). This shows the importance of tau structure in 
disease induction and tau spreading. And indeed, tau fibrils with different conformations where 
also found in patients with different tauopathies (Fitzpatrick et al., 2017; Falcon et al., 2018; 
Zhang et al., 2019). The initial reason for the aggregation and amyloid formation of tau in 
sporadic and genetic cases of AD and other neurological diseases is still unknown. Sup35 is 
a prion protein in yeast which also changes its confirmation and forms in-register beta sheet 
structured amyloids, with Sup35NM constituting its prion domain (Gorkovskiy et al., 2014). 
Similar to tau, Sup35NM forms fibrils with different confirmations and these different fibril 
confirmations lead to a different level of infectivity of the respective Sup35NM strains (Ohhashi 
et al., 2010). We were now able to show that Sup35NM promotes tau aggregation in vitro as 
well as in vivo. We were therefore able to demonstrate that in principle a natural prion from a 
species present in the human microbiome is able to cause the aggregation of a prionoid like 
tau protein, thereby starting a pathological cascade of conformational changes like the one 




Strikingly, in a first trial the inoculation of App23 mice, overexpressing human amyloid 
precursor protein (APP) bearing the pathogenic Swedish mutation (Sturchler-Pierrat et al., 
1997), with Sup35NM solution, also led to an acceleration and accentuation of the formation 
of Aβ aggregates in the brains of those mice.  
Furthermore, in a mouse model for amyloid protein A amyloidosis seeding with Sup35 fibrils 
resulted in an accelerated amyloid formation of amyloid protein A (AA) (Lundmark, Westermark 
and Olse, 2005). This is additional prove that the seeding potential of prions is mainly based 
on structural similarities, in this case in-register beta sheet amyloids, and not similarities in the 
DNA sequence of the respective proteins.  
Our results are also in coherence with the fact, that in AD early tau aggregation occurs in the 
olfactory bulb and approximately 90% of AD patients show olfactory dysfunction as an early 
symptom, which correlates with a higher tau burden in the brains of prodromal AD patients 
(Doty, 2003; Arnold et al., 2010; Risacher et al., 2017). The nasal sensors are in close contact 
to exogenous agents and the microbiome in the nasopharyngeal cavity and they are 
anatomically connected with the limbic system, which is also affected early in AD (Ulrich, 
1985). Therefore, the olfactory system delivers a potential gateway for exogenous prions and 
other xenobiotics to enter the central nervous system without the need to pass the blood brain 
barrier (Brai and Alberi, 2018; Rey, Wesson and Brundin, 2018). Olfactory deficits are also 
present in other neurodegenerative diseases especially Parkinson and Huntington disease 
(Moberg and Doty, 1997; Takeda et al., 2014). In Parkinson disease  impaired olfaction is also 
one of the earliest signs often predating the diagnosis by 2 years (Ross et al., 2006). 
Additionally, researchers could show that injection of α-synuclein fibers into the olfactory bulbs 
of WT mice results in olfactory deficits and a spreading of α-synuclein which is reminiscent of 
the pattern observed in early stages of Parkinson (Rey et al., 2016) 
The fact that, pathological protein aggregates affect olfactory regions prior to other regions in 
the brain, suggests that the olfactory system might be particularly vulnerable for protein 
aggregation  in neurodegenerative diseases (Rey, Wesson and Brundin, 2018). Due to this 
evidence tests for olfactory function have been included in the diagnostic tools for Parkinson 
and AD (Devanand et al., 2000, 2010; Miller and O’Callaghan, 2015; Yoon et al., 2015; Lafaille-
Magnan et al., 2017). Further evidence for the involvement of fungal material in AD comes 
from a study where researchers were able to show fungal infection in 100% of the central 
nervous system (CNS) samples form AD patients they examined while at the same time 0% 
of the examined CNS samples of healthy control patients showed any signs of fungal infection 
(Pisa et al., 2015). Thereby, fungal material could be detected extracellularly as well as in 





The fungal species detected in the brains of the patients include Saccharomyces cerevisiae, 
Candida albicans and Malassezia globosa. Fungal material was also found in the blood of AD 
patients (Alonso et al., 2014; Pisa et al., 2015) were it could interact with Aβ and influence 
vascular disease as indicated by our in vivo trials with Aβ and Sup35NM. Depending on the 
study up to 90% of AD patients exhibit cerebrovascular pathology (Kalaria, Akinyemi and Ihara, 
2012; Brickman et al., 2018), therefore a further investigation of the interaction of fungal 
material with Aβ or other compounds present in the blood of AD patients could also be of 
particular interest.  
An amyloid inducing interaction between two proteins of human origin was shown for α-
synuclein and islet amyloid polypeptide (IAPP) aka amylin (Valbuena, Villegas and Azcarate, 
2018). Under physiological conditions IAPP plays an adaptive role in metabolism and glucose 
homeostasis, by helping to control gastric emptying, suppressing the release of glucagon and 
insulin and helping to regulate satiety (Westermark, Andersson and Westermark, 2011). 
Phosphorylated α-synuclein deposits were found in the pancreatic β cells of 93% of Parkinson 
patients, 68% of diabetes mellitus patients and 17% of healthy controls. Interestingly while α-
synuclein and IAPP where co-expressed in the pancreatic β cells of all participants an 
interaction between the two proteins occurred only in subjects showing cytoplasmic deposits 
of phosphorylated α-synuclein in healthy as well as in diseased participants. In in vitro seeding 
trials preformed IAPP amyloid seeds accelerated the formation of α-synuclein fibrils while 
preformed α-synuclein amyloid seeds actually inhibited the formation of IAPP fibrils (Horvath 
and Wittung-Stafshede, 2016). This is in line with the fact that patients with type 2 diabetes 
(T2D) have a higher risk to develop Parkinson while Parkinson patients where not shown to 
have a higher risk to develop T2D (Xu et al., 2011; Santiago and Potashkin, 2014; Pagano et 
al., 2018) This indicates, that fibrils from a protein with a faster aggregation rate are able to 
accelerate the aggregation of monomers from a protein that has a slower aggregation rate. 
This fits well with our results about Sup35NM and tau aggregation in vitro where after 3 days 
of incubation there was a brought mixture of Sup35NM fibrils visible for Sup35NM while 
unseeded WT-tau did not show any fibrils at this time point, unless it was seeded with 
Sup35NM fibrils. 
Another potential way on how prions from the microbiome could influence the aggregation of 
prionoids with key roles in neurodegeneration is the migration of prions from the gut 
microbiome to the brain via the vagus nerve. And indeed in a model for Parkinson the injection 
of α-synuclein fibrils into the gut of mice led to the misfolding of endogenous  α-synuclein to its 
pathological form in the brain, while dissection of the vagus nerve prevented any cerebral α-





The results from Parkinson patients are less clear, while a Swedish study found a small 
protective effect for vagus nerve dissection starting 5 years post-surgery (Liu et al., 2017) a 
Danish study on the same topic was not able to find any significant difference between patients 
and controls with an intact vagus nerve (Tysnes et al., 2015). This suggests, that the vagus 
nerve is not the only route which can be used by α-synuclein in order to enter the brain.  
More evidence for gut derived α-synuclein seeding comes from a recent study in which 
scientists could show that gastrointestinal exposure of mice overexpressing human α-
synuclein to bacterial amyloid protein curli leads to increased α-synuclein aggregation in the 
gut and the brain of those mice (Sampson et al., 2020). This is further evidence for the ability 
of non-human prions to seed the aggregation of human prionoids involved in the development 
of neurodegenerative diseases. Interestingly, in the same study it was shown, that curli is 
unable to seed tau aggregation. 
Together with the results from the one directional seeding of IAPP and α-synulein this opens 
the perspective for a hierarchic prion cross-seeding system, separating highly cross-seeding 
competent prions from others, which might be more “seedable”. 
Sup35 is a translation termination factor and acts as a suppressor of nonsense mutations in 
Saccharomyces cerevisiae (King et al., 1997; Kushnirov, 2000). Sup35, in its prion form, 
occurs in wild yeasts on grapes and on Saccharomyces cerevisiae strains of commercial wine 
yeast (Halfmann et al., 2012). Saccharomyces cerevisiae strains able to form Sup35 amyloid 
aggregates were also found in yeast samples from some breweries and some commercial fruit 
(Kelly, Busby and Wickner, 2014).  
Interestingly, the exposure of millions of humans to the bovine spongiform encephalopathy 
(BSE) only resulted in a small number of patients with variant Creuzfeld-Jakob disease (vCJD). 
It is estimated that in the UK alone 10 million individuals consumed prion contaminated beef 
(Chen and Wang, 2014), however only 177 cases of vCJD were reported in the UK, with the 
majority of cases detected between 1995 and 2005 and only a few cases from 2012 to 2016 
(Comoy et al., 2017). In contrast to this low case numbers, in an anonymized survey in the UK 
disease-associated prion protein (PrPd) was found in 16 out of 32000 samples from human 
appendices (Noel Gill et al., 2013). This indicates an overall prevalence of 493 per million for 
the UK population and therefore a significant number of PrPd carriers without any symptoms of 
vCJD. In accordance with these results in another study scientist discovered small amounts of 
the pathogenic conformer of PrP in the brain autopsies of healthy volunteers (Yuan et al., 
2006). Additionally, acquired human prion diseases often have very long incubation periods 
reaching up to three decades in patients with iatrogenic PrPd infections or Aβ transmissions by 
contaminated growth hormone or gonadotropin and even five decades in  people infected with 




Altogether these results suggest that a certain event is needed to trigger the spread of 
pathological prion proteins in the brains of carriers.  
In this context, exposure to microbiotic or exogenous non-mammalian prions early in life would 
be followed by a long incubation period in sporadic AD. Thus, our putative theory might explain 
the relationship between the biology of aging and the biology of AD pathology. 
In theory, it could be that in many cases prions like Sup35 simply don’t get into direct contact 
with proteins like tau in the brain of their carriers for a very long time period, which would be 
necessary for them to induce a conformational change. Additionally, it could also be that the 
interaction of prions with their target proteins and the spreading of the resulting misfolded 
prionoids could be influenced by certain immunological events. In analogy, for herpes simplex 
virus type 1 (HSV-1) the site of entry is a critical factor for the development of a latent or active 
infection (Hafezi et al., 2012) and the deprivation of nerve growth factor leads to the 
reactivation of herpes virus from the latent phase (Wilcox and Johnson, 1987). There seems 
to be a connection between inflammation and AD however, with all the research done on this 
specific sub topic so far it is still not known if inflammation is a cause, contributor, or secondary 
phenomenon in AD and trials with anti-inflammatory drugs have been a major disappointment 
so far, as they have been for virtually all other therapeutics that have attempted to address the 
underlying pathogenesis of AD (Wyss-Coray and Rogers, 2012; Ozben and Ozben, 2019). 
Interestingly, some people suffering from a long-lasting active inflammatory disease like 
rheumatoid arthritis, tuberculosis and malaria develop amyloid protein A (AA) amyloidosis a 
disease where a N-terminal fragment of serum AA forms β-sheet fibrils that are deposited  
predominantly in kidney liver and spleen (McAdam, 1978; Johan et al., 1998; Solomon et al., 
2007). Why some of these patients develop AA amyloidosis and others not is unknown so far. 
However, it was shown that amyloid fibrils are able to highly accelerate the formation of AA 
fibrils in a mouse model. These fibrils include Sup35 and AA amyloid deposits from duck- or 
goose derived foie gras (Lundmark, Westermark and Olse, 2005; Solomon et al., 2007). 
Therefore, these results give a potential hint for an interaction between inflammation and prion-
like seeding where one event fuels the other.  
In light of this our data primarily call for the advanced analysis of the cross-species cross-
seeding capacity of Sup35 and other non-human prions, the search for such fungal, bacterial 
or plant prions in samples of the human microbiome, as well as the further study of cross-
seeding effects of Sup35 on amyloid-β and other human prionoids, e.g., α-synuclein. In this 
context it would also make sense to analyze the tau filaments, resulting from Sup35NM 





Therefore, the structure of the filaments could be determined and compared to the already 
known structures of tau fibrils from different tauopathies (Fitzpatrick et al., 2017; Falcon et al., 
2018; Zhang et al., 2019), consequently, allowing to find out if the Sup35NM induced curly tau 
structure is a new structure and if it has common features with the pathological tau detected in 
tauopathies. Understanding the initiation of prion formation in sporadic neurodegenerative 
disorders will be pivotal for the long-awaited generation of preventive or curative approaches 
for these devastating disorders.   
When thinking about a potential treatment for AD another important point to consider is the 
potential long term effect of the neurotoxic stress caused by misfolded pathological proteins 
like tau. In order to address this question, we studied the long-term fitness of P301SxTau62 
(P62) mice after their recovery from a reversible tau induced paresis. The paresis had been 
caused by the co-expression of full-length P301S mutant tau together with a wild-type 3R tau 
fragment from AS 151-421 (Δtau). After the expression of Δtau had been stopped at the age 
of 3 weeks the mice recovered completely from their severe hind limp paresis in the timespan 
of another 3 weeks besides the continued expression of P301S tau. Interestingly, in old age 
the recovered P62 mice did show a slightly better motoric fitness as their heterozygous 
littermates, only expressing P301S tau since their birth, and lower levels of tau pathology in 
their brains. This might be due to the fact that paralyzed P62 mice only have oligomeric tau 
forms in their brain while fibrillary tau is absent. When we inoculated the brains of Alz17 mice, 
expressing the longest human tau isoform and not developing filamentous tau aggregates by 
themselves, with brain stem homogenates of paralyzed P62 mice no formation of tau fibrils 
was observed. 
In contrast, control seedings with the brain stem homogenates of aged P301S mice, containing 
fibrillary tau, induced a granular focal tau pathology, primarily in the ipsilateral dorsal fornix 
above CA1 and the fimbria. This is further evidence, that the structure of tau aggregates plays 
a crucial role when it comes to tau pathology spreading in the brain via prion-like template 
transmission.  
It also speaks for the development of therapies which target tau before the formation of tau 
fibrils was initiated and asks for caution regarding the use of seeding based assays for the 










Here we demonstrate that the yeast Sup35NM prion domain can promote the formation of tau 
aggregation in vitro and in vivo. This provides first evidence for heterotypic cross-species 
seeding of a human neurodegenerative prion-like protein by a yeast prion. This calls for further 
analysis of the cross-species seeding competence of non-human (fungal, bacterial, viral) 
prions and prion-like neurodegenerative proteins, as well as research on the presence of non-
human prions in the human microbiome. 
In the second project we demonstrate that high molecular weight tau oligomers can provoke a 
severe, but reversible neurotoxicity. Rescued mice do not suffer from long-term sequelae, what 
augurs well for early therapeutic interventions targeting oligomeric tau forms. Furthermore, we 
confirm that these early toxic tau species lack classical seeding competence. Confirming the 
importance of an appropriate β-amyloid structure for tau seeding and spreading. This asks for 
caution regarding the use of seeding based assays for the detection of very early preclinical 
disease manifestations of tauopathies. It also warrants for a deepened analysis of early, non-
fibrillary toxic tau forms in the future 
Altogether there are still many open questions concerning AD and neurodegenerative diseases 
in general. However, there is immense evidence, that the conformation of tau plays a crucial 
role in the development of AD and other tauopathies (Arnold et al., 2013; Clavaguera et al., 
2013; Sanders et al., 2014; Kaufman et al., 2016; Falcon et al., 2018; Scheckel and Aguzzi, 
2018; Zhang et al., 2019).  
As tau plays several important roles in the development and maintenance of brain function 
(Lee and Rook, 1992; Hernandez and Avila, 2007) a simple deactivation or clearance of tau 
cannot be used to cure these diseases. Therefore, the best strategy for the prevention of AD 
seems to be the conservation of the functional physiological structure of tau. If this can be 
achieved by the removal of exogenous prions, which deliver a template for pathological tau 
seeding, the modification of post-translational modifications of tau or a combination of both has 
to be further investigated.  
It will still take at least some years to answer the questions concerning the origin, the 
progression and the potential healing of AD. In this context I am proud and happy that we were 










×R    × microtubule binding repeats  
3R    3 microtubule binding repeats  
AA    amyloid protein A  
AcMNPV   Autographa californica multiple nucleopolyhedrovirus  
AD   Alzheimer disease 
AEP    asparagine endopeptidase  
APOE-ε4  apolipoprotein E, type 4 allele  
APP    amyloid precursor protein  
APP   amyloid precursor protein  
Aβ   amyloid-beta  
B6 mice   C57BL/6 mice  
BBB    blood brain barrier  
BSE    bovine spongiform encephalopathy  
CAA   cerebral amyloid angiopathy  
CBD    cortico basal degeneration  
CBP    cAMP-response element binding protein (CREB)-binding protein  
Cdk5   cyclin-dependent kinase-5  
CJD    Creutzfeldt-Jakob disease  
CK1    casein kinase 1  
CNS    central nervous system  
CTE    Chronic traumatic encephalopathy  
DPBS    Dulbecco's phosphate-buffered saline  
FAD    familial Alzheimer’s disease 
FTDP-17  frontotemporal dementia with parkinsonism linked to chromosome 17  
FTLD-tau   frontotemporal lobar degeneration-tau  
GSK-3   glycogen synthase kinase-3  
HDAC6  histone deacetylase 6  
HSV-1   herpes simplex virus type 1  
htau    human tau  




IPTG    Isopropyl β-d-1-thiogalactopyranoside  
LDPrD   prion-like domain of Arabidopsis protein Luminidependens  
MAPKs   mitogen-activated protein kinases  
MAPs    microtubule-associated proteins  
MAPT    Microtubule-associated protein tau  
MARKs   microtubule affinity-regulating kinases  
MT    microtubule  
N279   asparagine residue 279  
NFTs   neurofibrillary tangles  
NTs   neuropil threads  
O-GlcNAc   N-acetylglucosamine  
O-GlcNAcylation  addition of β-linked N-acetylglucosamine  
P62   P301SxTau62  
PD    Prion disease  
PDPKs   proline-directed protein kinases  
PEP    postencephalitic parkinsonism  
PiD    Pick's, disease  
PKA    cAMP-dependent protein kinase A  
PMSF    phenylmethylsulfonyl fluoride  
PP2A    protein phosphatase 2A  
PP5   phosphatase 5  
PrP    prion protein  
PrPd    disease-associated prion protein  
PrPSc    PrPs β-sheet structured amyloid  
PS1    presenilin 1  
PS2   presenilin 2  
PSA   puromycin-sensitive aminopeptidase 
PSP    progressive supranuclear palsy  
SAD   sporadic Alzheimer’s disease  
SIRT1    sirtuin 1  
T2D    type 2 diabetes  
TEM    transmission electron microscopy  




WT    wild type  
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